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REGULATION OF SPG4 AND KATNB1 GENE EXPRESSIONS BY ELK1 
TRANSCRIPTION FACTOR 
SUMMARY 
Cytoskeleton is a network within the cell responsible for some cellular activities such 
as determining cell shape, providing cell movement and transport of some molecules. 
Microtubules are member of this network and have roles in chromosome segregation 
during mitosis, vesicular transport, axon formation and giving specific shapes of 
neurons. Microtubule severing is one of the major mechanisms that take role in 
formation of special neuron morphology. There are three microtubule severing 
enzymes called spastin, katanin and fidgetin. Spastin is encoded by SPG4 gene. 
However katanin is a heterodimer and its subunits p60 and p80 are encoded by two 
different genes KATNA1 and KATNB1, respectively. p60-katanin has the enzymatic 
activity for severing microtubules, while p80-katanin regulates role of p60-katanin in 
terms of stimulation or inhibition of p60-katanin activity.  
It is known that these enzymes are related with some neurological diseases. For 
instance, mutations in SPG4 gene lead to hereditary spastic paraplegia. Although 
exact mechanism has not been yet clear, it is thought that mutations in the SPG4 
gene cause lack of short microtubules needed in axon ends, owing to loss of 
microtubule severing activity of spastin; or failure of vesicular transport due to 
accumulation of mutant spastin on microtubule in axon ends. Besides of mutations, 
regulation of  SPG4 gene expression has also an effect on onset of disease. Katanin 
was found to be related with Alzheimer disease. In its unphosphorylated form, tau 
protein normally provides stabilization of microtubules and protects microtubules 
from the activity of severing enzymes. Hyperphosphorylation of tau results in 
dissociation of tau from microtubules and so microtubules become accessible for 
severing enzyme katanin. It is thought that this process may result in Alzheimer 
pathology. 
Elk1 is a transcription factor that has repressor and activator domains. The SUMO 
modification on repressor domain is necessary for inhibition of the target gene 
expression. However, when Elk1 is phosphorylated by extracellular signal such as a 
mitotic signal, Elk1 is de-SUMOylated and increases expression of target gene.  
In this study, the regulation of SPG4 and KATNB1 gene expressions by Elk1was 
investigated in human neuroblastoma cells.  
The repressive effect of Elk1 on spastin promoter was determined by using luciferase 
reporter assay and the reason for the repression is thought to be SUMO modification. 
Therefore new construct that did not include the repressor domain was constructed. 
According to the reporter assay data, Elk1 without repressor domain increased the 
promoter activity, whereas wt-Elk1 did not. This result was confirmed by analyzing 
mRNA and protein levels with real time PCR and immunostaning, respectively.  
Subsequently, PMA treatment was performed in order to de-SUMOylate Elk1 via 
phosphorylation. Following reporter gene assay, PMA treated and Elk1 transfected 
xx 
 
cells showed higher promoter activity compared to untreated and Elk1 transfected 
cell.  
Our observation indicated that, Elk1 acts as an activator on KATNB1 gene promoter 
differently than SPG4 promoter The results for KATNB1 gene were firstly confirmed 
in mRNA level by  performing real time PCR. Then SUMOylation of Elk1 was 
triggered by using KCl. According to the reporter assay data, KCl treated and Elk1 
transfected cells showed lower promoter activity compared to untreated and Elk1 
transfected cells. Increase in p80-katanin protein level by Elk1 and decrease of p80-
katanin protein level by KCl treatment were also shown with immunostaining and 
western blot analysis, respectively. 
xxi 
 
 
SPG4 VE KATNB1 GEN ANLATIMLARININ ELK1 TRANSKRİPSİYON 
FAKTÖRÜ İLE DÜZENLENMESİ 
ÖZET 
Hücre iskeleti tüm sitoplazmaya yayılan hücrenin şekil almasında, hareketinde, hücre 
içi molekül taşınması gibi ana mekanizmalarda görevli bir ağdır. Ökaryotik 
hücrelerde hücre iskeleti üç farklı yapıdan oluşmaktadır. Bunlar mikrofilamentler 
(aktin filamentler), ara filamentler ve mikrotübüllerdir. 
Mikrofilamentler, hücrede en fazla bulunan proteinlerden biridir ve evrimsel süreçte 
oldukça korunmuştur. Hücrenin şekil kazanmasında, hücre bölünmesinin sitokinez 
evresinde önemli roller üstlenen mikrofilamentler, globular aktinlerin ATP hidrolizi 
yardımıyla polimerizasyonu ile filament aktine dönüşür. Ara filamentler ise 
genellikle zar yapılarına yakın kısımlara yerleşmişlerdir. Örneğin çekirdek zarına çok 
yakın kısımlarda lamin adı verilen ara filamentler bulunur. Bunlar zara mekanik 
destek sağlarlar. Bunların haricinde hücreler arası bağların oluşumunda da görevleri 
vardır.  
Hücre iskeleti üçüncü elemanı olan mikrotübüller hücre bölünmesi sırasında 
kromozomların kutuplara çekilmesinde, hücrenin hareket edebilmesinde, hücrede 
vezikül taşınımında, nöronlarda akson oluşumunda ve nöronal şeklin kazanımında 
önemli rol oynar. Mikrotübüller hücrelerde stabil ve stabil olmayan iki farklı yapıda 
görülmektedir. Mikrotübüllerin α ve β tübülin adı verilen monomerlerinin 
polimerizasyonu ve depolimerizasyonu mikrotübüllere “dinamik instabilite” diye 
adlandırılan özelliği kazandırır. Bu dinamizm, mikrotübüllerin uzayıp kısalmasını 
sağlar. Stabil mikrotübüller ise nöron gibi özelleşmiş hücrelerde bulunur. Çünkü 
nöronların, örneğin hücre gövdesinde üretilen proteinlerin akson uçlarına kadar 
taşınabilmesi için ray görevi görecek sabit bir yapıya ihtiyacı vardır. Bu stabilite 
mikrotübül ilişkili proteinler (MAP) tarafından kontrol edilir. 
Miktotübüller ile ilgili bilinmesi gereken diğer bir nokta da kesim mekanizmasıdır. 
Nöronların özel morfolojilerinin oluşmasında başı çeken mikrotübül kesimidir. 
Çünkü polimerizasyon ve depolimerizasyonun neden olduğu sadece uç kısımlarda 
meydana gelen uzalıp kısalma, nöron morfolojisinin oluşması için gerekli olan 
dallanma sürecinde zaman ve hız açısından yetersiz kalır. Uzun bir mikrotübülün 
daha kısa parçalara ayrılması daha avanajlıdır. Ayrıca mikrotübüllerin bir başka yere 
taşınabilmesi için de kesilmesi gerekir. Yani mikrotübül taşınabilirliği, mikrotübül 
boyu ile ters orantılıdır. Şu ana kadar spastin, katanin ve fidgetin adı verilen üç kesim 
enzimi tanımlanmıştır. Her üç enzim de ATP’yi parçalayarak işlev gören ATPaz 
ailesinin üyeleridir. 
Spastin, SPG4 geni tarafından kodlanırken, bir heterodimer olan katanin KATNA1 ve 
KATNB1 genlerinden kodlanan ve sırasıyla p60 ve de p80 diye isimlendirilen alt 
birimlerden oluşur. Kataninde enzimatik aktiviteyi gösteren asıl alt birim p60-
katanindir. p80-katanin bu enzimatik aktiviteyi düzenleyendir ve bazı tanımlanmış 
bölgeleri ile p60-kataninin mikrotübülleri kesmesini arttırabilmektedir. 
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Nöronlarda bu iki enzimin dağılımına bakıldığında, kataninin daha çok akson 
boyunca yoğunlaştığı, spastinin ise hücrenin kısa uzantılarının olduğu dallanma 
bölgelerinde fazla bulunduğu gözlemlenmiştir. Böylece spastinin mikrotübülleri daha 
kısa parçalara ayırdığı, kataninin ise daha uzun parçalar halinde kestiği gösterilmiştir.  
Bu iki enzimin çeşitli nörolojik hastalıklarla ilişkili olduğu bilinmektedir. Spastin 
genindeki delesyon, insersiyon gibi mutasyonların ya da alternatif kırpılmaların 
herediter spastik paraplejiye sebep olduğu gösterilmiştir. Spastin proteininin bu 
hastalıkla ilgisi tam olarak aydınlatılamamış olmakla beraber, mutant spastin 
proteininin mikrotübül kesme fonksiyonunu yitirmesinden dolayı akson uçlarında 
ihtiyaç duyulan kısa mikrotübüllerin sağlanamaması veya mutant formdaki spastinin 
akson uçlarındaki mikrotübüller üzerinde birikmesiyle veziküler transportun 
aksaması olası sebepler olarak bildirilmiştir. Mutasyonların haricinde gen anlatımının 
düzenlenmesinin de hastalığın ortaya çıkmasında etkili olacağı düşünülmüş ve 
spastin promotör karakterizasyonu yapılmıştır.  
Katanin ise Alzheimer hastalığı ile ilişkilidir. Çünkü mikrotübüllerin stabil kalmasını 
sağlayan ve normalde mikrotübüllerle etkileşim halinde olan tau proteininin 
hiperfosforilasyonu, mikrotübüllerin stabilitesini kaybetmesine neden olur. Böylece 
mikrotübüller katanin ile kesilmeye açık hale gelir. Bu sürecin Alzheimer hastalığı 
patolojisine neden olabileceği düşünülmektedir. Tüm bunlar göz önüne alındığında 
spastin ve kataninin hücre içindeki miktarları, dolayısıyla gen anlatım süreçleri ve 
düzenlenmesi oldukça önem kazanmaktadır. 
Bu genlerin anlatımlarının düzenlenmesinde etkili olan Elk1 transkripsiyon 
faktörünün rol oynadığı bulunmuştur. Elk1 hem gen anlatımını baskılayıcı hem de 
aktive edici bölgeler içermektedir. Elk1’in hedef gen anlatımını azaltması için aynı 
zamanda baskılanma bölgesinde SUMO adı verilen bir modifikasyon geçirmesi 
gerekmektedir. Ancak hücre dışı sinyallere bağlı olarak örneğin mitotik sinyallerle 
Elk1’in aktivatör bölgesi fosforilasyona uğradığında SUMO modifikasyonu ortadan 
kalkar ve Elk1 hedef gen anlatımını arttırır. 
Bu çalışmada spastin kodlayan SPG4 geninin ve p80-katanini kodlayan KATNB1 
geninin anlatımlarının insan nöroblastoma hücrelerinde Elk1 transkripsiyon faktörü 
ile nasıl düzenlendiği araştırılmıştır 
Elk1’in spastin promotörü üzerinde baskılayıcı etkisinin olduğu tespit edilmiş ve bu 
etkinin baskılayıcı bölgede gerçekleşen SUMO modifikasyonundan kaynaklandığı 
düşünülmüştür. Bu sebeple baskılayıcı bölge içermeyen yeni bir dizi oluşturulmuştur. 
Elk1 ve baskılayıcı bölge içermeyen Elk1’in spastin geni anlatımına olan etkileri 
karşılaştırıldığında, baskılayıcı bölge içermeyenin gen anlatımını arttırdığı bildirici 
gen (lusiferaz) deneyi ile saptanmıştır. Bu sonuç gen anlatım sürecinin kapsadığı 
transkripsiyon ve translasyon basamaklarında da sırasıyla mRNA ve protein 
düzeyinde de gerçek zamanlı polimeraz zincir reaksiyonu (PZR) ve immun boyama 
teknikleri ile doğrulanmıştır. Ardından SUMO modifikasyonunu elimine etmek ve 
promotör üzerindeki azaltıcı etkiyi tersine çevirebilmek için Elk1’in fosforile olması 
sağlanmıştır. Bunun için nöroblastoma hücrelerine mitotik bir ajan olan PMA 
bileşeni uygulanmış ve bildirici gen testi yeniden yapılmıştır. Buna göre PMA ile 
muamele edilmiş hücrelerde SPG4 gen anlatımının, PMA ile muamele edilmemiş 
hücrelere göre arttığı gözlemlenmiştir. Bu deney sonucu da protein düzeyinde 
doğrulanmıştır. 
Elk1’in KATNB1 promotörü üzerinde SPG4’den farklı olarak aktivatör rol oynadığı 
bildirici gen testi ile belirlenmiştir. Deney sonucu mRNA düzeyinde de gerçek 
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zamanlı PZR yöntemiyle doğrulanmıştır. Elk1’in KCl kimyasalı ile SUMO 
modifikasyonuna uğraması tetiklenmiştir. KCl’ye maruz bırakılan hücrelerde 
diğerlerine göre daha az promotör aktivitesi belirlenmiştir. Elk1’in p80-katanin 
proteini seviyesini arttırdığı ve KCl uygulanmış hücrelerde p80-katanin protein 
üretiminin azaldığı immun boyama ve Western blotlama tekniği ile gösterilmiştir. 
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1. INTRODUCTION 
1.1 Cytoskeleton 
Cytoskeleton is a network of protein filaments which have role in the formation of 
cell shape, supporting of the cell membrane, providing self-generated movement and 
transporting cellular vesicles throughout the cell. Eukaryotic cells contain three main 
types of cytoskeletal filaments (Figure 1.1). Microfilaments also called actin 
filament, intermediate filaments, and microtubules can be distinguished from each 
other on the bases of their diameter, type of subunit, and subunit arrangements 
(Alberts et al., 2008; Lodish et al., 2003). 
 
Figure 1.1: A eukaryotic cell stained for visualizing its cytoskeleton. Nucleus (blue), 
microfilament (red) and microtubules (green) (Alberts et al., 2008). 
1.2 Microfilaments (Actin Filaments) 
Actin is one of the most abundant intracellular proteins in a eukaryotic cell (Figure 
1.2). Actin genes are highly conserved; however the various actin isoforms exhibit 
minor sequence differences and generally perform different functions. Actin  
filaments are highly  dynamic  structures  that  participate  in  many cellular  
functions  such as  the  maintaining cell polarity and morphology, generating force 
for movements, intracellular  trafficking, maintenance of cell junctions and 
cytokinesis. The organizational flexibility of the actin cytoskeleton permits a cell to 
gain many different shapes as microvilli on the surface of intestinal epithelial cells 
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vastly increase the cell surface area and enhance nutrient absorption. On the other 
hand, the regular network of actin filaments forms stable and differentiated cell 
morphology such as neurons. 
 
Figure 1.2: Actin filaments stained with red (Campbell and Reece, 2005). 
Actin subunit is globular monomer called G-actin and has ATP and Mg
+2
/ K
+
 
binding site at the center of the molecule. ATP is hydrolyzed immediately after the 
monomer is incorporated into an actin filament.  The linear chain of G-actin subunits 
forms filamentous polymer called F-actin in the presence of ATP, Mg
+2 
and K
+
.  
Actin filaments consist of two-stranded helical polymers of the F-actins. The 
concentration of G-actin is also critical since this process is reversible. Actin 
molecules polymerize when G-actin is above the critical concentration, and 
depolymerize when G-actin is below the critical concentration.  ATP  hydrolysis  is  
not  required  for  polymerization,  but  it  is required  to  promote  depolymerization  
(when  it  is  converted  to  ADP). Two of these forms, ATP–G-actin and ADP–F-
actin predominate in a cell. They are cross-linked and bundled together via different 
accessory proteins (Alberts et al., 2008; Lodish et al., 2003). 
1.3 Intermediate Filaments 
Intermediate filament proteins form parallel homo or heterodimers rope-like 
structures and typically criss cross the cytosol, forming an internal framework that 
stretches from the nuclear envelope to the plasma membrane (Figure 1.3). 
Intermediate filament network is located adjacent to some cellular membranes, where 
it provides mechanical support. For example lamin proteins are associated with each 
other and anchored to the inner nuclear membrane. This structure is called nuclear 
lamina. In the plasma membrane, intermediate filaments are attached by adapter 
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proteins to form cell junction which mediates cell-cell adhesion and cell-matrix 
adhesion.  
 
Figure 1.3: Immunofluorescence labeled intermediate filaments (Lodish et al.,2003). 
Unlike other members of cytoskeleton, intermediate filaments are assembled from a 
large number of different intermediate filaments and they are more stable. In 
addition, although microfilaments and microtubules have been strongly conserved in 
evolution, intermediate filaments family are very diverse. Intermediate filaments, 
except lamins, are tissue-specific. For example, keratins are found in epithelial cells 
and also form hair and nails, neurofilaments strengthen the long axons of neurons, 
vimentins provide mechanical strength to the muscle. The phosphorylation of 
intermediate filaments early in mitosis leads to their disassembly and break down of 
nuclear envelope. Reassemble of these intermediate filaments occur in late mitosis 
after dephosphorylation of the subunits (Alberts et al., 2008; Lodish et al., 2003). 
1.4 Microtubules 
Microtubules are composed of globular tubulin subunits called α- and β-tubulin 
(Figure 1.4). They are arranged in a hollow cylinder tubes with 25 nm diameter. 
Initially, α-tubulin and β-tubulin form heterodimer and subsequently these 
heterodimers build the protofilament. These protofilaments create the structure of 
microtubules. Varying in length from a fraction of a micrometer to hundreds of 
micrometers, microtubules are much stiffer than both microfilaments and 
intermediate filaments because of their tube-like construction (Alberts et al., 2008; 
Lodish et al., 2003). 
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Figure 1.4: (a) Structure of α -tubulin and β –tubulin, (b) assembly of microtubule 
(Alberts et al., 2008). 
Similar to microfilaments, microtubules have roles in certain cell movements, 
including the beating of cilia and flagella and the molecular trafficking in the 
cytoplasm. Cells contain microtubules in two different structures; stable, long-lived 
microtubules and unstable, short-lived microtubules. Stable microtubules are 
generally found in non-dividing cells. For instance, neurons contain long processes 
called axons and stable microtubules in axons not only support their structure but 
also provide transport throughout axons. On the other hand, unstable microtubules 
are found in cells that need to assemble and disassemble microtubule-based 
structures quickly. For example, in mitosis the polymerization and depolymerization 
of microtubules form the mitotic spindle apparatus that provides separation of 
chromosomes equally to the daughter cells (Lodish et al., 2003). 
The  structure  of  microtubule  is  organized  in  a  polar  manner  such  that  the α-
tubulin subunit  is  exposed  at  the  minus  end, where rapid depolymerization 
occurs,  while  the β-tubulin  subunit  is  exposed  at  the plus end, where rapid 
polymerization occurs (Risinger et al., 2009). In a tubulin dimer, non-exchangeable 
GTP is found at the N terminal site of α-tubulin, whereas the exchangeable 
nucleotide of β-tubulin is on the surface of the dimer and this determines 
polymerization or depolymerization state (Alberts et al., 2008). Microtubules  
comprising  GTP-bound tubulin  at  the  plus  end  are  stable  since  these  GTP  caps  
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strengthen  the lattice  of the microtubule. Hydrolysis an exchangeable GTP disrupts 
the microtubule stability. GTP cap is lost and microtubules start to shrink if GTP 
hydrolysis occurs more rapidly than the addition of subunits. This event is called 
“catastrophe” while a transition from a shortening phase to a growing phase is 
termed as “rescue”. Microtubules are switching between growth and shrinkage 
phases. This feature is entitled as dynamic instability (Lodish et al., 2003) (Figure 
1.5). 
 
Figure 1.5:  Growth and shrinkage of microtubule (Cheeseman and Desai, 2008). 
In addition to α-tubulin and β-tubulin, other member of tubulin superfamily is γ-
tubulin is localized in Microtubule Organizing Center (MTOC) such as centrosomes. 
Moreover it is also found in the cytoplasm as a part of a large complex called γ-
Tubulin Ring Complex (γ-TuRC), which is required to initiate the polymerization of 
the α/ β- tubulin into a microtubule. Therefore, the minus end of the microtubule is 
associated with the γ-TuRC complex (Job et al., 2003; Wiese and Zheng, 2006). 
Microtubule structure or stability is supported by a class of proteins called 
Microtubule Associated Proteins (MAPs). They bind to microtubule walls and 
promote either microtubule polymerization or disassembly of microtubule from 
microtubules ends (Hartman et al., 1998). Classical MAPs, such as MAP2 and tau, 
bind to the surface of the microtubules and neutralize the repulsive negative charge 
on the microtubule surface (Heald and Nogales, 2002). Coordination mistakes of 
these proteins may lead to diseases such as Alzheimer Disease (AD) (Baas and 
Qiang, 2005). 
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Since neurons are specialized cells and they do not divide, microtubules do not take 
part in the formation of mitotic spindle. Instead, microtubules in neurons are 
employed in elongation of axons (Karabay et al., 2004). The major events for axonal 
differentiation such as elongation, branching, navigation, retraction, are 
accomplished by changes in the configuration and behavior of microtubules (Baas 
and Buster, 2003). Moreover, microtubules also serve as roadway for transport of 
organelles or vesicles throughout axons (Baas, 1999). The minus ends of all axonal 
microtubules are oriented towards the base of the axon, but dendritic microtubules 
have mixed polarities (Figure 1.6) (Lodish et al., 2003). 
 
Figure 1.6: Microtubule organization in neurons (Lodish et al., 2003). 
1.5 Microtubule Severing 
The dynamic instability is not sufficient to explain all behaviors of microtubules 
observed in the cell. Some specialized cells like epithelial cells and neurons need 
non-centrosomal microtubules. There are three possible ways to create these non-
centrosomal microtubules: (1) the release of microtubules originally anchored at the 
MTOC, (2) de novo production and growth of microtubules in the cytosol, and (3) 
severing of microtubules at site remote from the centrosome (Quarmby et al., 2000; 
Quarmby and Lohret., 1999). Furthermore, the capacity of microtubule to move is 
inversely proportional to the length of the microtubule; shorter microtubule has more 
rapid movements (Baas et al. 2005). Thus, it is suggested that microtubule movement 
may be regulated by its length. There are two mechanism in regulation of length of 
microtubule: (1) addition/loss of tubulin subunits at the end of microtubule, and (2) 
internal breakage of the microtubule by microtubule severing enzymes (Casanova et 
al.,2009). 
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According to a recent study related to microtubule movement and called “cut and 
run”, the motor proteins, which provide transport of vesicle or microtubule, bind to 
all microtubule regardless of their length, yet it cannot transport longer microtubule. 
Since of shorter microtubule is mobile, long microtubule can only be transported 
after being severed into shorter pieces (Baas et al., 2005).  
Three microtubule severing enzymes have been identified until now: katanin, spastin 
and fidgetin. All of these three enzymes belong to the ATPases Associated with 
diverse cellular Activities (AAA) family of the ATPases and play critical role in 
essential cell process such as mitosis, neuronal development, cilia and flagella 
biogenesis (Casanova et al., 2009). 
Microtubule severing also has role in the formation of neuron structure. Especially 
katanin and spastin are important for the formation of filopodia, neuronal branching 
and axonal growth (Yu et al.,2008). In addition, dendrites and axons contain large 
numbers of noncentrosomal microtubules that are essential for architectural support 
and also act as railway for the transport of materials along the axon (Dent, et al., 
1999). 
1.5.1 Spastin 
Spastin is encoded by the SPG4 (SPAST) gene composed of 17 exons and 616 amino 
acids, and approximately 67.2 kDa. It contains two leucine –zipper and coiled– coil 
dimerization motif (Fonknechten et al., 2000; Hazan et al., 1999). The C-terminal 
part of the protein contains microtubule severing domain and microtubule binding 
domain (MTBD), which is necessary to bind to microtubule for severing. The N-
terminal part of spastin contain hydrophobic domain (HD), which is important for 
localization, and MIT domain, which acts role in microtubule interaction and 
trafficking (Figure 1.7) (Lumb et al., 2012). 
 
Figure 1.7: Spastin domains organization (Lumb et al., 2012). 
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The mutations in SPG4 gene most frequently (~40%) causes genetically inherited 
disease, Hereditary Spastic Paraplegia (HSP) that is a clinically and genetically 
heterogeneous disorder of which principal feature is progressive lower-limb 
spasticity, extremity weakness and difficulties in walking (Reid et al., 1999; Morita 
et al., 2002). The mutations on this gene can be missense, nonsense, splice site 
mutations, deletion or insertion which result in reduction of mRNA and protein level 
of spastin (Riano et al., 2009). A previous study shows that in addition to mutations 
in SPG4 gene, regulation of spastin gene expression by some transcription factors 
affects production of spastin protein as well. The reduction of spastin protein level by 
transcriptional regulation can be associated with HSP (Canbaz et al., 2011).  
1.5.2 Katanin 
Katanin is the most well characterized microtubule severing enzyme whose name is 
originated from the Japanese word for samurai sword “katana”. It is a heterodimer 
protein consisting of two subunits. Enzymatic subunit p60-katanin, which is named 
corresponding to its molecular weight (60 kDa), is encoded from KATNA1 gene and 
it has ATPase activity and severs microtubules. Other subunit p80-katanin has 80 
kDa molecular weight and is encoded from KATNB1 gene. It localizes katanin to the 
centrosome and regulates microtubule severing activity of p60 subunit (Hartman and 
Vale., 1999; Quarmby et al., 2000). In addition, p80 enhances the microtubule 
severing capacity of p60 subunit (Ahmad et al, 1999). 
The p60-katanin is 491 amino acid long polypeptide and its N-terminal region binds 
to microtubules and C-terminal region has ATPase activity, and it severs 
microtubule. The p80-katanin is 658 amino acids. Its N-terminal contains WD40 
repeat domain, a central proline rich domain, and the C-terminal domain is required 
for dimerization with the catalytic p60-katanin subunit (Karabay et al., 2004; 
Hartman et al., 1998; Hartman and Vale, 1999). The WD40 domain of p80-katanin 
can enhance p60 mediated microtubule severing by increasing affinity of p60 to 
microtubules. However, it is also indicated that the WD40 domain of p80-katanin 
might inhibit the microtubule-severing activity of p60 (McNally et al., 2000).  
According to the experimental data it is suggested that MAPs which provide stability 
for microtubules, protect the microtubule from severing enzymes. The 
phosphorylation of these MAPs results in their dissociation with microtubule and 
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thus enable katanin bind to microtubule to sever it. Not all MAPs, but tau offers 
strong protection against severing by either katanin or spastin. Therefore, 
hyperphosphorylation of tau causes it to dissociate from microtubules, so 
microtubules become more accessible to katanin. Baas and Qiang (2005) suggested 
that this process can cause AD pathology (Figure 1.8). 
 
Figure 1.8: Model for microtubule-based axonal degeneration in AD (Baas and 
Qiang, 2005). 
1.6 Transcriptional Regulation of Eukaryotic System 
In eukaryotic cells, multiple events such as decondensation of locus, nucleosome 
remodeling, histone modifications, binding of transcriptional activator or repressor 
and basal transcription machinery are required for transcription of protein-coding 
gene (Smale and Kadonaga, 2003). There are thousands of protein-coding genes and 
each of these proteins  has its own specific program for transcriptional control. The 
control of this process is predominantly mediated by numerous sequence-specific 
DNA binding factors (Kadonaga, 2004).  
Transcription is a complex process that depends on the collective action of the 
sequence-specific factors along with the core RNA polymerase II transcriptional 
machinery including chromatin remodeling factors that mobilize nucleosome 
structures, and variety of enzymes that catalyze the modification of histones and 
other protein (Kadonaga, 2004). 
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In eukaryotes, the core promoter providing a control point for regulated gene 
transcription serves as a platform for assembly of transcription preinitiation complex 
that includes TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH (transcription factor IIA, 
IIB, IID, IIE, IIF, IIH respectively) and RNA polymerase II which function 
collectively to specify the transcription start site (Thomas and Chiang, 2006). This 
collection  results in localization of RNA polymerase II at the correct initiation site, 
the core promoter (Smale and Kadonaga, 2003). This transcription preinitiation 
complex could only support basal transcription. This complex need “mediator”, a 
multiprotein complex composed of ~20 different proteins in order to respond to 
additional regulator proteins such as activator and enhancer (Figure 1.9) (Kornberg, 
2005). 
 
Figure 1.9: The illustration of eukaryotic transcription initiation complex (Alberts et 
al., 2008). 
The TATA box (also named the Goldberg-Hogness box after its discoverers) was the 
first core promoter element identified in eukaryotic protein-coding genes with 
TATAAA consensus sequence found 25 to 30 bp upstream of the transcription start 
site.  At first it was speculated that the TATA box might be exactly conserved and 
essential for transcription initiation. However along with sequencing and 
characterization of genes, ratio of promoters including TATA box reduced (Smale 
and Kadonaga, 2003).   
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1.7 ETS Domain Transcription Factor 
The ETS-domain family of eukaryotic transcription factor is composed of more than 
30 members and their structure has significant sequence similarity throughout their 
entire length, especially ETS-domain (Sharrocks, 2001, Oikawa and Yamada, 2003). 
Each protein exhibits an evolutionarily-conserved ETS-domain of about 85 amino 
acids residues (>95 % amino acid identity) that mediate binding to purine-rich DNA 
sequences with a central GGAA/T core consensus and additional flanking 
nucleotides (Figure 1.11) (Oikawa and Yamada, 2003). 
 
Figure 1.10: DNA-binding site of different ETS-domain transcription factors 
(Sharrocks et al., 1997). 
Many ETS family proteins are downstream target for signal transduction pathways 
affected by extracellular stimuli. Some post translational modifications occur on the 
protein and they often change their DNA binding ability, transcriptional activation, 
association with cellular partners, subcellular localization and/or protein stabilities. 
They activate or repress transcription of target gene together with other members of 
transcription factors and co-factors and play crucial role in regulation of numerous 
cellular function including apoptosis, development, differentiation and oncogenic 
transformation during both embryonic development and in the adult. In addition, it 
was shown that some family members have both repressive and simulative abilities, 
making the strict distinction impossible (Sharrocks, 2001). These signaling pathways 
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including Mitogen Activating Protein  kinase (MAPK), Extracellular Signal 
Regulated Kinase (ERK) 1 and 2, p38 and c-Jun N-terminal Kinase (JNK) and Ca
+2
-
specific signal activated by growth factors or cellular stress (Yordy and Muise-
Helmericks, 2000). 
ETS-domain family proteins can be classified into several subfamilies on the basis of 
their structural composition and their similarities in the DNA-binding ETS domain. 
The ETS domain localize in C-terminal region of most of them. However several 
ETS subfamilies like Ternary Complex Factor (TCF) subfamily have the ETS 
domain in their N-terminal regions (Figure 1.12) (Oikawa and Yamada, 2003). 
 
Figure 1.11: ETS-domain transcription factor subfamilies and their structures 
(Oikawa and Yamada, 2003). 
1.7.1 TCF family 
Ternary Complex Factor (TCF) family is the most studied subfamily of ETS domain 
factors. The first TCF transcription factor was identified in the nuclear extract of 
HeLa cells. This novel protein was called p62 due to its 62000 Da molecular weight. 
Then, it was shown to be homologous to Elk1 (Ets-like 1) protein, which was 
previously described by Hipskind et al (1991).  Later, two homologous proteins of 
Elk1, Sap1 and Net/Sap2 have been identified (Sharrocks, 2002). 
Their characteristic property is the ability to form ternary nucleoprotein complex 
with the Serum Response Factor (SRF) over the Serum Response Element (SRE) of 
the c-fos promoter (Figure 1.13) 
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Figure 1.12: Ternary complex formation on SRE site (Buchwalter et al., 2004). 
The TCFs have similar four regions known as A, B, C, D domain. The A domain 
also called ETS domain localizes in the N-terminal is responsible for DNA binding 
and contains a nuclear localization signal (NLS) and nuclear export signal (NES). It 
has also been demonstrated to act as a transcriptional inhibitor in a member of TCF 
subfamily called Elk1. The B domain interacts with the SRF and allows ternary 
complex formation. The C domain also called transactivation domain localizes in C-
terminal and is phosphorylated by MAP kinase pathway. The D domain is a docking 
site for MAP kinases and lies upstream from C domain. A second docking site FXFP 
motif within C domain is specific for ERK pathway. (Figure 1.14) (Buchwalter et al., 
2004). 
 
Figure 1.13: Structure of TCF subfamily members (Buchwalter et al., 2004). 
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1.8 Elk1 Transcription Factor 
Elk1 is the best studied member of TCFs family and has been widely studied in the 
context of cellular signaling (Nilsson et al. 2007). In addition to four domains 
mentioned above, Elk1 has also R motif at the central part of the protein. This motif 
dampens down the basal transcriptional activity of Elk1 and is sufficient to mediate 
transcriptional repression (Yang et al., 2002).  
In non-neuronal cells, Elk1 is restricted to nucleus as expected for a transcription 
factor; however in mature neuron it is expressed in both cytoplasmic and neuritic 
compartments in addition to the nucleus (Sgambato et al., 1998; Vanhoutte et al, 
2001). Elk1 localization in axon and dendrites of adult rat brain was previously 
shown (Sgambato et al., 1998).  Moreover Elk1 was found to be associated with 
neuronal microtubules in hippocampal culture and neuroblastoma cells. When Elk1 
is phosphorylated, it relocalizes to the nucleus (Demir et al., 2009). Neuronal 
isoform of Elk1, sElk1(short Elk1), expression of which is restricted to the nucleus, 
is lacking the first 54 amino acids of the ETS domain due to its translation start site 
in Elk1 sequence. Therefore truncated protein has different DNA binding property 
than full length protein.  The sElk1 plays an opposite role to Elk1. sElk1 antagonizes 
Elk1-mediated transactivation of SRE and promotes neuronal differentiation 
(Vanhoutte et al.,2001). 
Modifications of Elk1 have crucial roles in alteration of Elk1 activity on the target 
gene. There are two important modification on Elk1; phosphorylation and 
SUMOylation. Elk1 is a direct target for MAP kinase pathway and phosphorylation 
of Elk1 C-terminal transactivation domain stimulates the activator role of Elk1. On 
the other hand SUMOylation of Elk1 at R motif results in repressive effect of Elk1 
on the target gene expression (Yang et al., 2003). The modification of Elk1 is 
mentioned in details in the section 1.9.1. 
1.9 Post-Translational Modifications 
Post-translational modifications (PTM) of proteins lead to the functional diversity of 
the proteome by proteolytic cleavage or by the covalent addition of functional groups 
on proteins. These modifications include phosphorylation, glycosylation, 
methylation, ubiquitination, acetylation, SUMOylation. PTMs modulate the activity 
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of most eukaryote proteins and can affect protein activity, localization, turnover, and 
interactions with other cellular molecules such as proteins, nucleic acids, lipids, and 
cofactors (Mann and Jensen, 2003).  
Phosphorylation of proteins present in numerous pathways is a major regulatory 
mechanism in eukaryotic organism and causes conformational change in the 
structure of protein. Kinases phosphorylate proteins and phosphatases 
dephosphorylate proteins. Therefore proteins are switched between “active” or 
“inactive” states. Phosphorylation generally occurs on serine, threonine and tyrosine 
residues of proteins (Chang and Steward, 1998, Ciesla et al., 2011). The main 
process in which the major regulator is phosphorylation/dephosphorylation are cell 
cycle and apoptosis. Phosphorylation induces or inhibits specific cell cycle events. 
For example, cyclins are phosphorylated by specific cyclin dependent kinase and so 
cell cycle progress next step, or Rb hypophosphorylation is not sufficient to enter 
into G1 phase of the cell cycle. Rb should be hyperphosphorylated to begin the cell 
division mechanism. Furthermore chromosome condensation, nuclear envelope break 
down durin mitosis and transcription factor nuclear export are also regulated by 
phosphorylation that increases their affinity for a specific exportin, and many of cell 
surface receptors are activated by phosphorylation (Lodish et al., 2003). 
SUMO (Small Ubiquitin Related Modifier) is ubiquitin-like protein which changes 
the function of the substrate protein. Although ubiquitin has primary role on 
proteolytic degradation of target proteins, it can also regulate localization or activity 
of proteins. Otherwise SUMO conjugates to target protein like ubiquitin, but 
SUMOylation is not related with protein degradation. SUMO effects protein 
localization and activation similar to non-proteolytic activity of ubiquitin, and has 
important role in many cellular process including gene expression, chromatin 
structure, signal transduction. Although ubiquitin and SUMO have similar non-
proteolytic activity, they can cause different events after they modify the target 
proteins. For instance, modification of histones by ubiquitin usually increases gene 
expression whereas modification of histone by SUMO usually decreases gene 
expression. SUMO stimulates interaction with other proteins that have little or no 
affinity for the unmodified target protein.  
Four SUMO homologs have been described in mammals: SUMO-1, SUMO-2/3 and 
SUMO-4. Human SUMO-2 and SUMO-3 are 95% homologous at the protein level, 
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whereas SUMO-1 shows 47% homology. SUMO-4 is the least characterized isoform 
and its expression pattern is generally reported in the kidney (Salinas et al., 2004, 
Gill, 2004). Moreover 18% sequence similarity and similar protein folding are 
determined between SUMO-1 and ubiquitin by NMR analysis. However the 
localization of charged amino acid on the surface is very different from that 
ubiquitin. It is thought that SUMO binds to protein as monomer, however SUMO-1, 
SUMO-2 and SUMO-3, have been observed to form polymeric chains in vitro (Gill, 
2004).  
SUMOylation is a dynamic process. SUMO is attached to target protein through the 
action of enzymes including E1 activating enzyme, and the E2 conjugating enzyme 
Ubc9 that transfers the SUMO to protein. E3 ligase has role as bridge to facilitate the 
action of Ubc9. On the other hand SUMO is cleaved by SUMO1/ sentrin/ SMT3-
specific peptidase (SENPs) (Witty et al., 2010). 
A consensus SUMO motif, ѱKxE has been identified. Ѱ represent a hydrophobic 
amino acid, x represent any amino acid, and K is the target of SUMO conjugation 
(Rodriguez et al., 2001). Additionally the SUMO modification site commonly lies 
within inhibitory domain (Gill, 2004).  
In mammalian cells, SUMO modification of some proteins provides localization of 
these proteins to the nucleus (Gill.,2004). Moreover SUMO modification can 
negatively regulate gene expression through repressed transcription factor activity or 
promoted interaction with transcriptional co-repressor. For instance, SUMOylation 
of p300 stimulates association with histone deacetylase complex 6 HDAC6 and it led 
to reduction of histone acetylation at the target gene promoter (Girdwood et al, 
2003).  
Another mechanism of SUMO modification is about DNA repair system. Thymine-
DNA glycosylase enzyme (TDG) has role in base excision repair in response to DNA 
damage. SUMO modification on TDG alters its enzymatic activity due to it reduced 
affinity for DNA (Hardeland et al., 2002).  
1.9.1 Modifications of Elk1 
Elk1 transcription factor undergoes two post translational modifications; 
phosphorylation and SUMOylation. These two post translational modifications allow 
Elk1 to gain both activating or repressing functions. Typically, targets of Elk1 are 
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immediate-early gene activated by extracellular signals, where Elk1 permits transient 
and rapid gene activation as response. A tight control mechanism is required for this 
swift activation, hence dynamic interaction exists between activating MAPK and 
repressive SUMO pathways (Yang et al., 2003). 
Elk1 has two repression sites; one of them is ETS-domain and the other one is 
repression domain (R motif) that was identified by Yang et al. (2002). This study 
shows that amino acids between 230 and 260 in Elk1 comprise repression domain 
and is sufficient to repress transcription. The R motif of Elk1 contains three lysine 
residues K230, K249, K254, which are SUMO binding sites and are required for the 
repression of basal transcriptional activation. Moreover, glutamic acid residues are 
also necessary so that SUMO can recognize the target protein. Especially K249 and 
E251 are important amino acids to reduce gene expression of target protein. 
Mutations or deletions in any of these residues result in significant enhancement of 
gene expression (Yang et al., 2002, Yang et al., 2003). In addition, K249, V250 and 
E251 residues are also critical for enhancing the activities of histone deacetylase 
(Figure 1.15). Moreover R motif is thought to maintain Elk1 in an inactive state 
before activation by MAPK pathway (Yang et al., 2002). 
 
Figure 1.14: The critic SUMO binding residues of WT.Elk1 and consensus SUMO 
recognition amino acids (Salinas et al., 2004). 
Otherwise phosphorylation of Elk1 allows Elk1 to act as an activator and increase 
gene expression of the target. This phosphorylation occurs on Serine 383 and 389 
residues located at the C terminal (Figure 1.16). There are three MAPK pathways 
identified, whose targets are Elk1. The ERK cascade is stimulated by growth factors 
and mitogens. The JNK and p38 pathways respond to cytokines signals and stress 
conditions (Buchwalter et al., 2004). Phosphorylation of Elk1 by these pathways 
provides loss of SUMO conjugation of Elk1. Therefore Elk1 loses its repressive 
effect and gains activator effect on the target gene promoter (Yang et al., 2003). 
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Figure 1.15: SUMOylation and phosphorylation sites of Elk1 (Besnard et al., 2011). 
It was shown that phorbol 12-myristate 13-acetate (PMA) treatment induced 
phosphorylation of MAPK rapidly and increased their ability to phosphorylate Elk1 
in a human myeloid leukemia cell line (Hu et al., 2000). In addition, in 
phosphorylation dependent de-SUMOylation of Elk1by PMA, SENPs have role on 
cleaving of SUMO from substrate in HEK-293T cells (Witty et al., 2010). 
1.10 Aim of the Study 
Spastin and katanin sever microtubules by hydrolyzing ATP and this severing 
activity is required for important processes such as mitosis, neuronal development, 
axonal branching. Spastin is encoded by SPG4 gene, whereas katanin subunit p80 
and p60 are encoded by KATNB1 and KATNA1 genes, respectively. p60-katanin 
subunit shows enzymatic activity, while p80-katanin has role in regulation and 
localization of p60-katanin. The activity of p60-katanin can be stimulated or 
inhibited by p80-katanin.  
In our lab, the optimal promoters of SPG4 and KATNB1 genes were analyzed to 
determine the critical region for the regulation of transcription. 700 bp and TATA-
less promoter including critical CpG island was identified for SPG4 as an optimal 
promoter called S2 construct. 518bp and TATA-less sequence was identified for 
KATNB1 as optimal promoter and called F2 construct. In our current study S2 and F2 
constructs were used as optimal promoters. 
On the other hand, transcription factor Elk, which belongs to ETS domain family and 
TCF subfamily, regulates expression of SPG4 and KATNB1 genes. Elk1 has a 
repression domain (R motif) in the central part and activation domain at C-terminal 
region. It can act as either repressor or activator depending on the different promoter 
sites where these domains bind. When the R motif is SUMOylated, Elk1 has 
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repressive activity on the target gene promoter; otherwise transactivation domain of 
Elk1 is phosphorylated and increases expression as an activator. 
In this study, our aim is to identify the transcriptional regulation of SPG4 and 
KATNB1 genes by Elk1. Firstly we will intend to construction of Elk1.woR, which is 
without repression domain at central part of wild type Elk1, in order to understand 
effect of Elk1 on SPG4 optimal promoter when Elk1 cannot undergo SUMO 
modification. On the other hand, we aimed to determine effect of Elk1 on KATNB1 
gene expression. The three experimental methods will be designed to show in 
expressional, transcriptional and translational levels; dual-luciferase reporter assay, 
quantitative real time PCR, immunostaining and Western blotting, respectively. 
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1 Equipment 
Equipment used in this study is shown in the table below. 
Table 2.1: Laboratory equipment used in the study. 
Equipment Supplier Company 
Laminar Air Flow Cabinets FASTER BH-EN 2003 
Pipettes 
2.5µL, 10µL, 100µL, 200µL,  Eppendorf 1000µL,   
Finnpipette Thermo 
Electronic Pipette Finnpipette Thermo 
Centrifuges 
Biolab SIGMA 6K15, Beckman Coultier 
Microfuge®18, Beckman Coulter AvantiTM J-30 I, 
IECCL10 Centrifuge, 
Thermo Electron Corporation, Labnet, Labnet 
International C1301-230V 
Incubator with CO2 Biolab SHEL LAB 
Thermo Cycler Techne, TC-3000 
Vortex Heidolph, Reaxtop 
Quick Spin Labnet International, C1301-230V 
Magnetic stirrer VELP scientifica 
pH Meter Mettler Toledo MP220 
Light Microscope Olympus CH30 (USA) 
Hemacytometer FisherLab Scientific, 0267110 
Nucleofector Lonza, Amaxa 
Luminometre Thermo, Fluoroskan Ascent FL 
High Pressure Steam Sterilizer TOMY SX-700E 
Precision Balance Precisa 620C SCS 
Balance Precisa BJ 610 C 
Ice Machine Scotsman AF 10 
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Table 2.1 (cont’d.): Laboratory equipment used in the study. 
Electrophoresis Gel System 
Thermo EC MiniCell® PrimoTM 
EC320 Electrophoretic Gel System 
Power Supply 
EC250-90 Apparatus Corporation 
BIO-RAD 
SDS-PAGE Gel Electrophoresis System BIO-RAD MiniProtean 
Microwave Arçelik MD582 
UVIPhoto MW Version 99.05 
 for Windows 95 & 98 
UVItec Ltd. 
Spectrophotometers 
Shimadzu, UV-1601 
Thermo Scientific NanodropTM 2000c 
BIO-RAD Benchmark Plus 
Water Baths Memmert, Elektro-mag M 96 KP 
Thermomixer Eppendorf Thermomixer Comfort 
Shaker 
Forma Orbital Shaker, 
Thermo Electron Corporation 
Freezers 
UĞUR (+4 oC), 
UĞUR (-20oC), 
New Brunswick Scientific (-80 oC) 
DNA Sequencer Applied Biosciences 3100 Avant 
Light Cycler® 480 Roche 
LightCycler® 480 Multiwell Plate 384 Roche, 04729749001 
LightCycler®  480 Sealing Foil 50 foils  Roche,04729757001 
Luminomertical 96 well plate Lumitrac 200 
TCS SP2 SE Confocal Microscope Leica, Microsystems 
Trans-Blot® SD Semi-Dry Transfer Cell BIO-RAD 
Kodak Medical X-ray Processor   Kodak 
2.1.2 Commercial kits 
Commercial kits used in this study are shown in the table below 
Table 2.2: Commercial kits used in the study. 
Kit Supplier Company 
QIAprep Spin Miniprep Plasmid Purification Kit Qiagen, 27106 
QIAGEN EndoFree Plasmid Maxi Kit Qiagen, 12362 
QIAquick PCR Purification Kit Qiagen, 28104 
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Table 2.2 cont’d: Commercial kits used in the study. 
QIAquick Gel Extraction Kit Qiagen, 28706 
Endofree Plasmid Maxi Kit Qiagen, 12362 
BigDye® Terminator v3.1 Cycle Sequencing Kit APPLIED Biosystem 
Dual-Luciferase Reporter Assay System Promega, E1910 
Transfast Transfection Reagent Promega, E2431 
High Pure RNA Isolation Kit Roche, 11828665001 
Complete Lysis-M Roche, 04719956001 
RevertAid™ H Minus First Strand cDNA 
Synthesis Kit 
Fermentas, K1631 
Light Cycler 480 Probes Master Roche, 04707494001 
Amaxa
TM
 Cell Line Nucleofector Kit V Lonza, VCA-100 
20X LumiGLO® Reagent and 20X Peroxide Cell Signaling, 7003 
SuperSignal® West Femto Maximum Sensitivity 
Substrate 
Thermo, 34094 
Micro BCA™ ProteinAssay Reagent Kit Pierce, 23235 
Restore Western Blot Stripping Buffer Thermo Scientific 
2.1.3 Molecular cloning assay 
 Primers (Alpha DNA) 
 25 mM MgCl2 (Fermentas) 
 2 mM dNTP Mix (Fermentas) 
 Taq Polymerase 5u/µL (Fermentas) 
 10X Taq Buffer with KCl (Fermentas) 
 Mass RulerTM DNA Ladder Mix (Fermentas) 
 6X DNA Loading Dye (Fermentas) 
 Agarose Low EEO (Applichem) 
 EtBr (Merck) 
 KpnI Restriction Enzyme (Fermentas) 
 1X Buffer KpnI (Fermentas) 
 SalI Restriction Enzyme (Fermentas) 
 1X Buffer O (Fermentas) 
 BamHI Restriction Enzyme (Fermentas) 
 1X Buffer BamHI (Fermentas) 
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 T4 Ligase (Roche) 
 10X Ligation Buffer (Roche) 
 PEG 8000 (Fluka) 
 Tris Base (BDH Laboratory) 
 EDTA (Merck) 
 Boric Acid (Merck) 
 Molecular Biology grade Ethyl Alcohol (Fiedel-de Haën) 
2.1.4 Bacterial assay 
 Tryptone (BDH Laboratory) 
 Yeast Extract (Merck) 
 NaCl (Fluka) 
 Agar (Merck) 
 Ampicillin (Sigma-Aldrich) 
 Kanamycin (Sigma-Aldrich)  
 Glycerol (Fluka) 
2.1.5 Cell culture assay 
 25 cm2, 75 cm2 Tissue Culture Flask (TPP) 
 6 well, 24 well Culture Plate (TPP)  
 5 mL, 10 mL, 25 mL Serological Pipettes (TPP) 
 250 mL Vacuum Filtration System (TPP) 
 Poly-L-Lysine (Sigma-Aldrich) 
 0,22 µm Syringe Filtre (TPP) 
 10 mL, 20 mL Syringe (Set Inject) 
 Dulbecco’s Modified Eagle Medium (DMEM) 1X (Gibco) 
 Fetal Bovine Serum (Gibco) 
 L-Glutamine Solution, 200mM (Biochrom) 
 Penicilin/Streptomycin Solution 100X (Biochrom) 
 Trypsin-EDTA 0,25/0,02 Solution (Biochrom) 
 Phosphate Buffered Saline (PBS) 10X pH=7,2  (Gibco)  
 DMSO (Fiedel-de Haën) 
25 
 
2.1.6 Protein assay 
 SDS (AppliChem)  
 TEMED (AppliChem)  
 DTT (Merck) 
 Acrylamide (Sigma Aldrich) 
 Bis-acrylamide (Sigma Aldrich) 
 Bromophenol Blue (Merck) 
 SeeBlue® Plus2 Protein Standard ( Invitrogen) 
 Biotinylated Protein Ladder (Cell Signaling) 
 Nitrocellulose Paper (BIO-RAD)  
 3MM Whatman Filter Paper (Whatman) 
 Goat anti-mouse IgG antibody-HRP conjugate (Promega)  
 Goat anti-rabbit IgG antibody-HRP conjugate (Promega) 
 Tween-20 (AppliChem) 
 Skimmed milk powder (%5) (OXOID) 
 BSA (Fluka)  
 Rabbit monoclonal β-actin antibody (Cell Signaling) 
 Rabbit polyclonal SUMO2-3 antibody (Santa Cruz) 
 Rabbit monoclonal SUMO1 antibody (Cell Signaling) 
 Rabbit polyclonal Elk1 antibody (Santa Cruz) 
 Mouse monoclonal spastin antibody (Sigma) 
 Goat polyclonal katanin antibody (Santa Cruz) 
 Rabbit polyclonal katanin antibody (Sigma) 
 Alexa Flour 488 goat anti-rabbit (Invitrogen) 
 Alexa Flour 647 goat anti-mouse (Invitrogen) 
 Alexa Flour 647 goat anti-rabbit (Invitrogen) 
 Alexa Fluor 488 donkey anti-goat (Invitrogen) 
 DAPI (Sigma) 
 Mounting Medium (Sigma) 
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2.1.7 General chemicals 
 Ethanol (Riedel- de Haёn) 
 Methanol (Riedel- de Haёn) 
 Isopropanol (Fluka) 
 KCl (Fluka) 
 HCl (Applichem) 
 NaOH (Applichem) 
 MgCl2 (Merck) 
 MgSO4 (Fluka) 
 HEPES (Sigma) 
 CaCl2 (AppliChem) 
 Glucose (Merck) 
 Glicial Acetic Acid (Fluka) 
 Glycerol (Fluka) 
 Glycine (Merck) 
 Tricine (Merck) 
2.1.8 Buffers and solutions 
2.1.8.1 50X TAE buffer  
Stock solution 50X TAE buffer was diluted to 1X  as a working solution. It was used 
in DNA gel electrophoresis to prepare the gel and as the tank buffer. The content of 
this solution is shown in table 2.3. 
Table 2.3: Content of 50X TAE buffer. 
Content Concentration Amount 
Tris Base 
Glacial acetic acid 
EDTA 
dH2O 
2 M 
1 M 
50 mM 
242 g 
57,1 mL 
100 mL (0,5M) (pH=8) 
up to 1 L 
2.1.8.2 10X TBE buffer 
10X TBE buffer was prepared as a stock solution. 1X dilution of this buffer was used 
for DNA gel electrophoresis to prepare the gel and as the tank buffer. The content of 
this solution is shown in table 2.4. 
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Table 2.4: Content of 10X TBE buffer. 
Content Concentration Amount 
Tris Base 
Boric Acid 
EDTA 
dH2O 
890 mM 
890 mM 
20 mM 
108 g 
55 g 
40 mL (0,5M) (pH=8) 
up to 1 L 
2.1.8.3 Separating acrylamide solution 
Separating acrylamide solution was used for preparation separating gel. The amount 
and content of solution is given in table 2.5. 
Table 2.5: Content of separating acrylamide 
Content Amount 
Acrylamide 
Bis-acrylamide 
dH2O 
46,5 g 
1,5 g 
up to 100 mL 
2.1.8.4 Stacking acrylamide solution 
Stacking acrylamide solution was used for the preparation of stacking gel. The 
amount and content of solution is given in table 2.6. 
Table 2.6: Content of stacking acrylamide 
Content Amount 
Acrylamide 
Bis-acrylamide 
dH2O 
48 g 
1,5 g 
up to 100 mL 
2.1.8.5 2X sample buffer 
2X sample buffer was used to denature protein samples which were loaded on SDS-
polyacrylamide gel. Content of 2X sample buffer is shown in table 2.7. 
Table 2.7: Content of 2X sample buffer. 
Content Concentration Amount 
Tris-HCl 
SDS 
Glycerol 
Bromophenol Blue 
DTT 
dH2O 
0,125 M 
4 % 
20 % 
0,05 % 
0,15 M 
2,5 mL (0,5M) 
4 mL (10%) 
2 mL (100%) 
5 mg 
231 mg 
Up to 10 mL 
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2.1.8.6 Running buffer for SDS-PAGE  
Both the anode and the cathode buffers were used as SDS-PAGE running buffer, and 
their contents are given in table 2.8 and table 2.9, respectively. 
Table 2.8: Content of 1X anode buffer 
Content Concentration Amount 
Tris-Base 
dH2O 
0,2 M 
 
24,22 g 
Up to 1 L (pH=8,9) 
Table 2.9: Content of 1X cathode buffer 
Content Concentration Amount 
Tris-Base 
Tricine 
SDS 
dH2O 
0,1 M 
0,1 M 
 
182 g 
17,92 g 
1 gr (1%) 
Up to 1 L (pH=8,25) 
2.1.8.7 Towbin electrotransfer buffer 
Transfer buffer was used during Western blot analysis to reduce pH changes of the 
solution during the transfer of proteins from SDS polyacrylamide gel to 
nitrocellulose membrane. Content of this buffer is indicated in table 2.10.  
Table 2.10: Content of towbin electrotransfer buffer. 
Content Concentration Amount 
Tris-base 
Glycine 
Methanol 
SDS 
dH2O 
25 mM 
192 mM 
20 % 
0,05 % 
3 g 
14,4 g 
200 mL 
0,05 g 
up to 1 L 
2.1.8.8 10X TBS buffer 
TBS (with HCl) was prepared and used as blocking and washing buffer during 
Western blot analysis. 10X stock solution was diluted to 1X concentration with dH2O 
to obtain working solution. Content of TBS buffer is shown in table 2.11. 
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Table 2.11: Content of 10X TBS buffer. 
Content Concentration Amount 
Tris-base 
Glycine 
Methanol 
SDS 
dH2O 
25 mM 
192 mM 
20 % 
0,05 % 
3 g 
14,4 g 
200 mL 
0,05 g 
up to 1 L 
2.1.8.9 TBS-T buffer 
TBS-T solution was prepared for washing in Western blot analysis. Preparation of 
this buffer is shown in table 2.12. 
Table 2.12: Content of TBS-T buffer. 
Content Concentration Amount 
TBS 
Tween-20 
1X 
0,05 % 
1 L 
500 µL 
2.1.8.10 Blocking and incubation buffer 
Blocking and incubation buffer was used for blocking of membrane and incubation 
with primary antibody. Preparation of this buffer is shown in table 2.13. 
Table 2.13: Content of blocking and incubation buffer. 
Content Concentration Amount 
TBS-T 
Skimmed milk powder  
1X 
 
100 mL 
5 g 
2.1.8.11 PBS solution 
PBS solution was prepared by dissolving 1 PBS tablet within 100mL dH2O. 
2.1.8.12 PBST solution 
To prepare PBST solution, 2 mL Tween-20 was added into 1 L PBS solution. 
2.1.8.13 Elution buffer for immunoprecipitation 
50 mM Glycine (pH=2,8) was prepared and used as elution buffer. 
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2.1.9 Bacterial strains 
Escherichia coli DH5α strain [F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, 
recA1, endA1, hsdR17(rk
-
, mk
+
), phoA, supE44, λ-, thi-1, gyrA96, relA1] 
Escherichia coli dam- dcm- GM2163 strain [F
-
, dam-13::Tn 9 dcm-6 hsdR2 leuB6 
his-4 thi-1 ara-14 lacY1 galK2 galT22 xyl-5 mtl-1 rpsL136 tonA31 tsx-78 supE44 
McrA
-
 McrB
-
] (Fermantas, M009). 
2.1.10 Bacterial culture media and solution 
2.1.10.1 LB medium 
Luria Bertani (LB) Medium was prepared by dissolving 10 g tryptone, 5 g yeast 
extract, and 10 g NaCl in 1L dH2O. The media was sterilized by autoclaving for 15 
minutes (min) at 121°C.  To prepare a selective media, 50 µg/L ampicillin or 
kanamycin was added after the media was cooled down approximately to 55°C. 
2.1.10.2 LB-agar medium 
LB-Agar Medium was prepared by dissolving 10 g tryptone, 5 g yeast extract, 10 g 
NaCl and 20 g agar in 1L dH2O. The media was sterilized by autoclaving for 15 min 
at 121°C.  To prepare a selective media, 50 µg/L ampicillin was added after the 
media was cooled down approximately to 55°C. After mixing the medium with 
ampicillin, the content was poured into 10 mm Petri plates. 
2.1.10.3 SOC medium 
SOC medium was used to cultivate E.coli for 1 hour (h) after heat shock during 
transformation. 2 g tryptone, 5 g yeast extract, 0,058 g NaCl, 0,0186 g KCl, 0,095 g 
MgCl2, 0,23 g MgSO4 and 0,36 g glucose was resolved in 100 mL dH2O and 
sterilized at 121 
o
C by autoclaving for 15 min. 
2.1.10.4 CaCl2 solution 
CaCl2 solution was used in the preparation chemically competent E.coli cells that 
were further used in transformation. The solution contains 60 mM CaCl2, 10mM 
PIPES and 15 % glycerol in dH2O. pH was adjusted to 6,4 to dissolve PIPES and 
then was filter sterilized with 0,2 µm filter. 
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2.1.11 Vectors 
2.1.11.1 pGL2-basic and pGL3-basic 
The pGL2 and pGL3 luciferase reporter vectors (Promega, E1641 and E1751) 
provide a basis for the quantitative analysis of transcription factors that potentially 
regulate mammalian gene expression. These vectors carry the coding region for 
firefly (Photinus pyralis) luciferase that has been optimized for monitoring 
transcriptional activity in transfected eukaryotic cells. pGL2-basic and pGL3-basic 
vectors lack eukaryotic promoter and enhancer sequences, allowing maximum 
flexibility in cloning putative regulatory sequences. Expression of luciferase activity 
in cells transfected with pGL2-basic or pGL3-basic plasmids depends on insertion 
and proper orientation of a functional promoter upstream from luc or luc
+ 
respectively. pGL2-basic vector circular map is shown figure 2.1 (Promega 
Technical Manual, E1641) and pGL3-basic vector circle map is shown figure 2.2 
(Promega Technical Manual, E1751). 
 
Figure 2.1: pGL2-basic vector circular map (Promega Technical Manual, E1641). 
 
Figure 2.2: pGL3-basic vector circular map (Promega Technical Manual, E1751). 
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2.1.11.2 pRL-TK 
The pRL-TK vectors (Promega, E2241) providing constitutive expression of Renilla 
luciferase (Rluc) are control reporter vectors. The pRL-TK vector contains the 
Herpes simplex virus thymidine kinase (HSV-TK) promoter to provide low to 
moderate levels of Renilla luciferase expression in co-transfected mammalian cells. 
Renilla luciferase is a 36 kDa monomeric protein that does not require post-
translational modification for the activity. Therefore like firefly luciferase the 
enzyme may function as a genetic reporter immediately following translation. pRL-
TK vector circular map is shown in figure  2.3. 
 
Figure 2.3: pRL-TK vector circular map (Promega Technical Bulletin, E2241). 
2.1.11.3 pCMV6 vector 
pCMV6 vector is used as an expression vector (Figure 2.4). WT-Elk1, Elk1 without 
R domain (Elk1-woR) and constitutively active form of Elk1 (Elk1-VP16) sequences 
were inserted in this vector. KpnI, SalI, BamHI restriction endonucleases in multiple 
cloning site of vector were used for cloning. Wt- Elk1 is cloned into vector by using 
KpnI and BamHI restriction enzymes.  For the cloning of Elk1-woR sequence, firstly 
the vector was digested with KpnI and SalI restriction enzymes and upstream 
sequence of repression domain of Elk1 was ligated with the digested vector. Then the 
vector containing upstream region was again digested with SalI and BamHI 
restriction enzymes and downstream sequence was ligated to restricted vector.  
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Figure 2.4: pCMV6 vector circle map. 
2.1.12 Cell Line  
Human metastatic neuroblastoma cell line SH-SY5Y, which is a subline of SK-N-SH 
neuroepithelioma cell line was used. SK-N-SH cell line had been established from 
the metastatic neuroblastoma cells including bone marrow biopsy of a 4-year-old girl 
in 1970. 
2.1.13 Cell culture media 
2.1.13.1 SH-SY5Y culture medium 
SH-SY5Y culture medium was prepared with 10 % FBS, 2 mM L-Glutamine, 1X 
Penicilin/Streptomycin within DMEM containing 1 g/L glucose and then filter 
sterilized with 0,2 µm filter. 
2.1.13.2 SH-SY5Y freezing medium 
To prepare SH-SY5Y freezing medium, 5 % DMSO was supplemented within 
culture medium and then sterilized with 0,2 µm filter . 
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2.2 Methods 
2.2.1 Primer design 
Forward and reverse primers specific for expression vector pCMV6.Elk1.woR 
construct with appropriate flanking restriction site were designed by considering the 
general rules of primer design using Integrated DNA Technologies, Oligo Analyser 
3.1 tool (Url-1). KpnI, SalI, BamHI enzymes restriction sites were added to 5’ end of 
the primers for the first forward primer, first reverse primer and second forward 
primer, and second reverse primer respectively. Melting temperatures (Tm) of the 
primers were selected as close as possible in order to facilitate the optimum 
annealing temperature selection. GC content, melting temperature, hairpin and self-
dimer formations were checked by using IDT Scitools oligo analyzer. All primers are 
shown in table 2.14. 
Table 2.14: Primers used in the study. 
Primer Sequence (5’ 3’) Length Tm GC 
content 1.F ATAGGTACCATGGACCCATCTGTGACGCT 29 63.8 
oC 51.7 %
1.R AAGTCGACCGGGGTCAGGATGACCTGCA 28 67,9 oC 60,7 % 
2.F AAGTCGACCCACAGGAGGGCGTGCCA 26 69,4 oC 65,4 % 
2.R AAGGATCCTCATGGCTTCTGGGGCCCT 27 66,9 oC 59,3 % 
2.2.2 PCR 
Polymerase Chain Reaction (PCR) is used to amplify a specific region of a DNA 
strand. Therefore unlimited copies of single DNA molecule can be produced by this 
technique that is based on enzymatic replication in vitro. Borders of amplified 
fragments are defined with oligonucleotides named primers. These primers provide a 
binding site on template DNA for DNA polymerase. The buffer is used to preserve 
DNA polymerase in its natural confirmation and dNTP molecules are included to 
reaction mixture to be integrated into newly forming DNA molecules. After the 
related components were added, some different PCR programs were performed. For 
initial denaturation and denaturation steps, where two strands of DNA were 
separated, 94 
o
C was used. Annealing temperatures, where primers bind to the 
complementary regions of the DNA, were changed according to the primers melting 
tempetatures. Finally, in elongation and final extension steps where suitable bases are 
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arranged in an order 72 
o
C was used. PCR components are indicated in table 2.15, 
PCR programs also are indicated in table 2.16 and table 2.17. 
Table 2.15: PCR components for amplification. 
Component Volume 
Template 200 ng 
Forward Primer (25 mM) 1 µL 
Reverse Primer (25 mM) 1 µL 
10X Taq Buffer 2,5 µL 
dNTP (2 mM) 2,5 µL 
Taq DNA Polymerase 0,5 µL 
dH2O Up to 25 µL 
Table 2.16: PCR program for amplification upstream of R domain. 
Step Temperature Time Cycle 
Initial Denaturation 94 oC 3 min 1 
Denaturation 94 oC 1 min  
35 Annealing 65 
oC 45 s 
Extension 72 oC 1 min 
Final extension 72 oC 5 min 1 
Hold 4 oC ∞ - 
Table 2.17: PCR program for amplification of downstream of R domain. 
Step Temperature Time Cycle 
Initial Denaturation 94 oC 3 min 1 
Denaturation 94 oC 1 min  
35 Annealing 67 
oC 45 s 
Extension 72 oC 1 min 
Final extension 72 oC 5 min 1 
Hold 4 oC ∞ - 
2.2.3 Agarose gel electrophoresis for detection of PCR product 
After PCR amplification of DNA fragments, PCR products were analyzed on agarose 
gel electrophoresis. For 1,5 % gel, 0,6 g agarose was added in 40 mL 1X TBE buffer 
and gel solution was boiled in a microwave until the agarose was completely 
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dissolved. After cooling the solution to about 60 
o
C, ethidium bromide was added to 
the gel solution to a final concentration of 0,5 µg/mL. 
Then, the gel solution was poured into a gel casting tray and a proper comb was 
placed in the gel tray. After the gel had been solidified, the comb was removed and 
gel was placed in electrophoresis chamber containing the appropriate amount of 1X 
TBE buffer. An appropriate molecular weight marker (MassRuler
TM
 DNA Ladder, 
Fermentas) and PCR product samples that were mixed with the 6X loading dye 
depending on the volume were pipeted into the gel wells. Gel was run at 120 V for 
30 min. Ethidum bromide (EtBr) stained DNA bands were visualized with UV trans-
illuminator by the help of UV PhotoMW software. 
2.2.4 Purification of PCR product 
After PCR and visualization by agarose gel electrophoresis, the fragments were 
purified with Qiagen QIAquick PCR Purification Kit. The kit removes the protein 
contamination derived from polymerase or restriction enzymes. The principle of this 
purification is as followed: DNA adsorbs to the silica membrane in the presence of 
high concentrated choatropic salt while contaminants pass through the column with 
washing buffer. Finally the DNA molecules are released with low salt concentration 
elution buffer. The purification protocol is given below: 
 5 volume of Buffer PB to 1 volume of PCR sample was added and mixed. 
 After mixing, sample was transferred into collection filter tubes and 
centrifuged 1 min at 13.000 rpm at table top centrifuge. 
 Flow-through was discarded and 750 µL Buffer PE to wash was added. The 
filter tube was centrifuged at 13.000 rpm for 1 min. 
 Flow-through was discarded and filter tube was centrifuged at 13.000 rpm for 
an additional 1 min. 
 The filter was placed into a clean 1,5 mL microcentrifuge tube. 
 To elute DNA, 50 µL Buffer EB was added to the center of column, and the 
column was centrifuged for 1 min at 13.000 rpm. 
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2.2.5 Determination of DNA concentration 
The spectrophotometric analysis was used to determine recovery, purity and 
concentration of nucleic acid. The ratio of absorption at 260 nm vs 280 nm is 
commonly used to evaluate the purity of DNA with respect to protein contamination, 
since protein (in particular, the aromatic amino acids) tends to absorb at 280 nm. 
According to the literature, the ratio of absorbance (A260/A280) of a pure DNA 
solution is between 1,8 to 2,0. When protein contamination increases, the ratio 
decreases. 2 µL sample was placed onto a sensor and its concentration was 
determined with the help of NanoDrop 2000/2000c Operating Software. 
2.2.6 Restriction enzyme digestion of PCR products and the vectors 
The restriction endonucleases cut DNA from specific palindromic restriction sites in 
length of 4 to 8 bases. The restriction endonucleases are commercially available, and 
are used to generate DNA fragments for cloning experiments. In this study KpnI, 
SalI and BamHI restriction enzymes were used. Plasmid vector was cut at 37 
o
C for 4 
h and insert was cut overnight at 37 
o
C with 1X appropriate buffer (supplied by the 
manufacturer). Restriction reaction was completed by thermal inactivation and then 
DNA was purified from restriction mixture by using QIAquick PCR purification kit. 
Restriction reaction mixtures are given in table 2.18 
Table 2.18: Restriction reaction mixture. 
Content Amount 
Plasmid vector 1000 ng 
KpnI/ SalI/ BamHI 1 µL 
KpnI Buffer/ O Buffer/ BamHI Buffer 2 µL 
dH2O Up to 20 µL 
Insert 1000 ng 
KpnI/ SalI/ BamHI 1 µL 
KpnI Buffer/ O Buffer/ BamHI Buffer 2 µL 
2.2.7 Determination of restricted DNA fragment by agarose gel electrophoresis 
After digestion with restriction enzymes, samples were run on 1 % agarose gel 
prepared with 1X TAE buffer. Each 5 µL sample was mixed with 1 µL of 6X loading 
dye. MassRuler
TM
 DNA Ladder Mix was used to estimate the sequence size. 
38 
 
Electrophoresis was applied at 120 V for 30 min. Pictures of gels were taken under 
UV light with a trans-illuminator, with the help of UV PhotoMW software. 
2.2.8 Purification of cleaved PCR product and vector 
The cleaved PCR product was purified with Qiagen QIAquick PCR Purification Kit 
as described in section 2.2.4. The purification of cleaved vector from the agarose gel 
was performed with Qiagen QIAquick Gel Extraction Kit. The purification protocol 
is given below. 
 DNA fragment was excised from the agarose gel with a clean, sharp scalpel. 
 After weighing the gel slice in a colorless tube, 3 volume of Buffer QC was 
added to 1 volume of gel. 
 The tube was incubated at 50 oC for 10 min to dissolve the gel. 
 1 gel volume of isopropanol was added to the sample and mixed. 
 A QIAquick spin column was placed in a provided 2 mL collection tube. 
 The sample was centrifuged for 1 min at 14.000 rpm at table top centrifuge. 
 Flow-through was discarded and the column was placed back in the same 
collection tube. 
 0,5 mL of Buffer QG was added to the column and centrifuged for 1 min at 
14.000 rpm. 
 Flow-through was discarded  
 To wash, 0,75 mL of Buffer PE was added to wash to the column and 
centrifuged for 1 min at 14.000 rpm. 
 Flow-through was discarded and the column was centrifuged for an additional 
1 min at 14.000 rpm. 
 The column was placed into clean 1,5 mL microcentrifuge tube. 
 To elute DNA, 50 µL Buffer EB was added to the center of column, and the 
column was centrifuged for 1 min at 14.000 rpm. 
2.2.9 Ligation 
Purified insert and vectors were ligated with Roche T4 ligase according to 1:3 
molecular ratios. Ligation was performed overnight at room temperature. After 
overnight incubation, T4 DNA ligase was inactivated at 65 
o
C for 10 min. Ligation 
reaction mixture is shown in table 2.19 
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Table 2.19: Reaction mixture for ligation. 
Content Amount 
Plasmid vector 300 ng 
Insert DNA 900 ng 
10X T4 Buffer 1,5 µL 
PEG 8000 1,5 µL 
T4 Ligase 1 µL 
dH2O Up to 15 µL 
2.2.10 Competent cell preparation - CaCl2 method 
The bacterial competent cells have been chemically treated to allow the foreign DNA 
or plasmid to be taken in. To prepare competent cells, the protocol is given below. 
 E.coli-DH5α cells were taken from a glycerol stock culture by scraping with a 
tip and it was put in 5 mL LB medium and incubated overnight at 37 
o
C in 
orbital shaker. 
 The following day, 100 mL LB medium was inoculated with 5 mL culture 
solution and was incubated at 37 
o
C in orbital shaker. Cell density was 
measured by spectrophotometer at OD600 and when it was reached to 0.6, the 
bacteria were transferred to 50 mL prechilled sterile ultracentrifuge tubes and 
incubated on ice for 10 min. 
 The cells were centrifuged at 1600 x g for 7 min at 4 oC, and then supernatant 
was discarded. 
 Each bacterial pellet was resuspended in 10 mL ice-cold CaCl2 and 
centrifuged for 5 min at 1600 x g, the supernatant was discarded. 
 Each bacterial pellet was resuspended in 10 mL ice-cold CaCl2 and they were 
incubated on ice for 30 min. 
 Centrifgation was performed again at 1600 x g for 5 min at 4 oC 
 Each pellet was resuspended completely in 2 mL of CaCl2 
 The competent cells were distributed into prechilled sterile microfuge tubes 
each contains 50 µL and they were stored at -80 oC. 
For 50 mL CaCl2 solution content is shown in table 2.20. 
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Table 2.20: CaCl2 solution content. 
Content Concentraiton Amount 
CaCl2.2H2O 
PIPES 
Glycerol 
dH2O 
60 mM 
10 mM 
15 % 
- 
0,442 g 
0,15 g 
7,5 mL (from 100 %) 
Up to 50 mL 
2.2.11 Transformation 
For the transformation procedure, the competent cells were taken out from -80 
o
C 
and thawed on ice. The ligation mixture was mixed with competent cells and the tube 
was incubated on ice for 30 min. Then the tube was placed in 42 
o
C for 45 sec and 
put back on ice for 2 min. 80 µL SOC medium was added and then culture was 
incubated at 37
 o
C for 1 h in orbital shaker. Culture was plated on selective medium 
with appropriate antibiotic (LB-Amp). Plates were incubated overnight at 37 
o
C.  
2.2.12 Colony PCR 
Colony PCR was performed to ensure selecting right colonies which were carrying 
inserts. Procedure of the colony PCR is given below: 
 10 µL sterile dH2O was put into PCR tube and a tip of each colony was 
resuspended. 
 Mixture was incubated in thermal cycler at 85 oC for 10 min. 
 Then PCR mixture mentioned in table 2.21 was added into tubes.  
 The PCR program is shown in table 2.22 
 The amplified fragment was controlled with agarose gel alectrophoresis as it 
was given in section 2.2.3. 
Table 2.21: PCR mixture for colony PCR. 
Component Volume 
Template+water 10 µL 
Component Volume 
Template  
Forward Primer (25 
mM) 
1 µl 
Reverse Primer (25 
mM) 
1 µl 
10X Taq Buffer 2,5 µl 
dNTP (2 mM) 2,5 µl 
Taq DNA Polymerase 0,5 µl 
Forward Primer (25 mM) 1 µL 
Reverse Primer (25 mM) 1 µL 
10X Taq Buffer 2,5 µL 
dNTP (2 mM) 2,5 µL 
Taq DNA Polymerase 0,5 µL 
dH2O 7,5 µL 
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Table 2.22: PCR program for colony PCR. 
Step Temperature Time Cycle 
Initial Denaturation 94 oC 3 min 1 
Denaturation 94 oC 1 min  
30 Annealing 65 
oC 45 s 
Extension 72 oC 1,5 min 
Final extension 72 oC 5 min 1 
Hold 4 oC ∞ - 
2.2.13 Small scale plasmid DNA preparation (mini-prep) 
Plasmid preparation was performed by using QIAGEN, QIAPrep Spin Miniprep Kit 
for small scale (mini) preparation, following instruction of the manufacturer. In this 
procedure, plasmid DNA was released from bacteria by alkaline lysis and removed 
all the RNA in the lysate by RNase. Then in the presence of chaotropic salt 
(guanidine HCl), DNA has ability to bind selectively to glass fiber fleece in a 
centrifuge tube and remains bound. Washing steps was performed to remove 
contaminating bacterial components, and then low salt elution buffer was added in 
order to remove DNA from the glass fiber fleece. 
The protocol of QIAPrep Spin Miniprep Kit, QIAGEN is as follows: 
 5 mL of LB containing selective antibiotic was inoculated with positive 
colony and the culture was incubated at 37 
o
C with 250 rpm shaking 
overnight. 
 Overnight culture was centrifuged 5000 rpm for 5 min. Supernatant was 
discarded and pellet was resuspended in 250 µL Buffer P1 containing RNase 
A and transferred to a microcentrifuge tube. 
 250 µL Buffer P2 was added and mixed thoroughly by inverting the tube 4-6 
times. 
 350 µL prechilled Buffer N3 was added and mix immediately and thoroughly 
by inverting the tube 4-6 times. 
 Suspension was centrifuged for 10 min at 13.000 rpm in a table top 
microcentrifuge. 
 The supernatant was transferred to the QIAPrep spin column by pipetting. 
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 Filter tube assembly was centrifuged at 13.000 rpm for 1 min. The 
flowthrough was discarded. 
 750 µL Buffer PE was added to the wash the column and centrifugation was 
performed at 13.000 rpm for 1 min.  
 Flow through was discarded and tube was centrifuged for an additional 1 min. 
to remove residual was buffer. 
 QIAprep column was placed in a clean 1,5 mL microcentrifuge tube. 50 µL 
Buffer EB was added to the center of column to elute DNA. Column was let 
standing for 1 min and centrifuged for 1 min. 
2.2.14 Sequencing 
DNA sequencing is the process of determining the nucleotide order of a given DNA 
fragment. For sequencing dye terminator sequencing was performed. This is 
accomplished by using different fluorescent dye labeled dideoxynucleotide chain-
terminators, which fluorescence at different wavelengths. 
2.2.14.1 Sequencing PCR 
Sequencing PCR is special typeof PCR in which single strand of DNA is amplified. 
Each dNTP is labeled with a different fluorescent tag; therefore resultant DNA 
fragment is fluorescently labeled. Single strand of DNA is desired to be exploited 
since 2 strands apparently interfere with the fluorescence of each other. Thus, only 
one primer is used in sequencing PCR. The reaction is performed in dark in order to 
preserve fluorescence. The reaction mixture preparation is shown in table 2.23. 
Table 2.23: Sequencing PCR mixture. 
Content Volume 
Big dye reaction mix 2 µL 
5X sequence mixture 2 µL 
 Template DNA 200 ng 
Forward /Reverse primers (25 mM) 0,5 µL 
dH2O Up to 10 µL 
The sequence reactions were performed using a thermal cycler with the following 
program mentioned in table 2.24. 
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Table 2.24: Sequencing PCR program. 
Step Temperature Time Cycle 
Initial Denaturation 95 oC 5 min 1 
Denaturation 95 oC 45 sec  
40 Annealing 55 
oC 45 sec 
Extension 60 oC 4 min 
Final Extension 60 oC 8 min 1 
Hold 4 oC - ∞ 
2.2.14.2 PCR purification for Sequencing 
Since PCR product was contaminated with polymerase, a subsequent purification 
was performed. All the purification steps were performed in dark in order to preserve 
fluorescence. The protocol is as follows: 
 10 µL PCR product was taken into microcentrifuge tube then 2 µL of 3 M 
NaAC and 50 µL ice-cold 95% ethanol were added to tube and incubated on 
ice for 30 min. 
 Mixture was centrifuged at 14.000 rpm for 30 min. Supernatant was 
discarded. 
 Pellet was resuspended in 200 µL ice-cold 70% ethanol and centrifuged 
14.000 rpm for 15 min. Supernatant was discarded. 
 Tube was incubated at 95 oC for 5 min with caps open (in order to evaporate 
residual ethanol). 
 20 µL of Hi-Di formamide was added to DNA pellet for elution and the 
mixture was vortexed vigorously and spun down 
 Tube was again incubated at 95 oC for 5 min with caps closed. 
 Tube was put on ice. 
 Tube was kept at 4 oC till use. 
2.2.14.3 Alignment of sequence results 
Nucleotide alignments were made both with BLAST tool (Url-2) and Clustal W 
program (Url-3) in order to compare the sequences obtained after sequencing with 
the original sequences. 
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2.2.15 Large scale plasmid DNA preparation (maxi-prep) 
After confirmation of the sequence data and assuring that none of the constructs 
possess any mutation, each construct was transformed with E.coli dam-/dcm- 
GM2163 strain in order to prevent any methylation that would interfere the 
transcription factor binding, according to the previously described transformation in 
section 2.2.11. After the colonies emerged the insert containing plasmids were 
reproduced in large scale and purified with QIAGEN, Endofree® Plasmid Maxi kit. 
This kit is chosen because subsequent to large scale production the plasmids are 
going to be used to transfect SH-SY5Y neuroblastoma cell line which is a sensitive 
cell line. Endotoxins, which are cell membrane components of Gram-negative 
bacteria (E.coli) strongly influence transfection and increased endotoxin levels lead 
to sharply reduced transfection efficiencies. Plasmid isolation procedure is as 
follows: 
 5 mL of LB containing selective antibiotic inoculated with positive colony 
and the culture was incubated at 37 
o
C for 8 h on orbital shaker. 
 100 mL LB medium with appropriate antibiotic was inoculated with 100 µL 
of starter culture and grown at 37 
o
C overnight on orbital shaker. 
 Overnight culture was centrifuged at 5000 rpm for 1 h at 4 oC. 
 Supernatant was discarded and pellet was resuspended in 10 mL Buffer P1 
and transferred to a 50 mL centrifuge tube. 
 10 mL Buffer P2 was added and mixed thoroughly by inverting the tube 4-6 
times and incubated at room temperature for 5 min. 
 10 mL prechilled Buffer N3 was added and mixed immediately and 
thoroughly by inverting the tube 4-6 times. 
 Lysate was poured into barrel of the QIAfilter Cartridge and incubate at room 
temperature for 10 min. Then the lysate was filtered into a 50 mL tube. 
 2,5 mL Endotoxin removal buffer (ER) was added to the filtered lysate, and 
mixed by inverting the tube 10 times, and incubated on ice 30 min. 
 During the incubation QIAGEN-tip 500 was equilibrated by applying 10 mL 
Buffer QBT and the column was allowed to empty by gravity flow. 
 The filtered lysate was applied to the QIAGEN-tip and allowed to enter the 
resin by gravity flow. 
 QIAGEN-tip was washed with 2 x 30 mL Buffer QC. 
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 DNA was eluted with 15 mL Buffer QF. 
 DNA was precipitated by adding 10,5 mL room temperature isopropanol to 
the eluted DNA and centrifuged immediately at 5000 rpm for 1 h at 4 
o
C. 
 After carefully decanting the supernatant DNA pellet was washed with 5 mL 
of endotoxin-free room temperature 70 % ethanol and centrifuged at 5000 
rpm 1 h at 4 
o
C. 
 The supernatant was carefully decanted without disturbing the pellet. 
 The pellet was air-dried for 5 min, and the DNA was redissolved in 300 µL 
endotoxin-free Buffer TE. 
2.2.16 Preparation of cell culture 
2.1.16.1 Transferring the stock cell to culture flask 
A frozen stock of SH-SY5Y cells were taken -80 
o
C and after the cells were thawed 
in 37 
o
C water bath. They were diluted with SH-SY5Y culture media of which 
content was given in section 2.1.13.1, and centrifuged for 5 min at 900 rpm. Cell 
pellet was dissolved with medium and transferred to the culture flasks. 
2.1.16.2 Cell counting 
Growing medium was removed and cells were detached by 1 mL Trypsin-EDTA 
treatment for 2 min at 37 
o
C. Then trypsin-EDTA solution was inhibited by 10 mL 
medium and cells were suspended Then 10 µL suspension was taken and put onto the 
hemocytometer, cells were counted as the number of cells per 25 square (1 mm
2
). 
The cell number calculation is given below: 
10
4
 (constant number) x Amount of counted cell = Cell number/ml 
Total cell number = Cell number/ mL x Total volume of cells (10 ml)            (2.1) 
2.1.16.3 Cell passage 
After cells were lifted and cell density was determined, cells were put into the 
centrifuge tubes and centrifuged 900 rpm for 5 min. The supernatant was discarded 
and pellet was resuspended with culture medium and 1x10
6
 cells were transferred to 
clean culture flask. 
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2.1.16.4 Cell freezing 
After cell passage, cells resuspended in medium were transferred to freezing tube 
with freezing medium for future experiments. Estimated cell number for per freezing 
tube was 1x10
6
 cell / mL. 
2.2.17 Transfection of SH-SY5Y cells for forced experiment 
Forced experiment is co-transfection of cells with vector containing promoter and 
another vector containing transcription factor. Transfection is the process to 
introduce a foreign DNA into the cell. In this study DNA was inserted into SH-SY5Y 
cells by lipofection. The synthetic cationic lipids that can form liposome are 
incubated with DNA. These liposomes interact with DNA through electrostatic 
interaction between the negatively charged nucleic acid and positively charged head 
group of synthetic lipid, and fuse with cultured cells. The liposome complex 
neutralizes the negatively charge of the nucleic acids, allowing association of the 
complex with the negatively charged cell membrane. Entry of the liposome complex 
into the cell may occur by the processes of endocytosis or fusion with plasma 
membrane via the lipid moieties of the liposome. The optimal amount of control 
vector to use in cotransfections is the minimum amount that gives significant reporter 
activity above background (background is measured in samples transfected with only 
the test vector, in our study pGL2_basic and pGL3_basic). Different amounts were 
tried for optimization and 7:1 ratio of test vector: control vector were determined as 
optimum for SH-SY5Y neuroblastoma cell line. Transfection contents are given in 
table 2.25 and table 2.26, and the transfection procedure is as follow. 
 After cells were detached and cell number was calculated (section 2.1.16.2), 
and 50.000 cells per well were seeded on plated 24 well tissue culture plate 2 
day before the transfection so that the cells were approximately 80 % 
confluent on the day of transfection. 
 1 µg of plasmid DNAs are diluted in 200 µL DMEM (1X) and vortexed and 
quick spun. 
 Promega’s transfection reagent Transfast was added to 1:3 ratio to the DNA 
mixture according to the ratios given in the table below and vortexed and 
quick spun briefly for the formation of DNA liposome complex, and 
incubated for 15 min at room temperature. 
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 The growth medium was removed from the cells and transfection mixture was 
added gently in order to prevent cell detaching and cells returned to the 37 
o
C, 
5 % CO2 incubator for 1 h. 
 After incubation, 500 µL medium was added to each well. 
 The cells were returned to the 37 oC, 5 % CO2 incubator for 48 h before 
analysis. 
Table 2.25: Transfection content for pGL2-S2 forced experiment. 
Construct name 
*pGL2-
S2  
wt-
Elk1  
Elk1-
woR  
Elk1-
VP16  
pCMV-
Myc. 
pRL-TK 
Control. 
Transfast 
reagent 
pGL2-S2 700 ng - - - 200 ng 100 ng 3 µL 
pGL2- basic 700 ng - - - 200 ng 100 ng 3 µL 
pGL2-S2 Elk1 700 ng 200 ng - - - 100 ng 3 µL 
pGL2- basic 
Elk1 
700 ng 200 ng - - - 100 ng 3 µL 
pGL2-S2 Elk1-
woR 
700 ng - 200 ng - - 100 ng 3 µL 
pGL2- basic 
Elk1-woR 
700 ng - 200 ng - - 100 ng 3 µL 
pGL2-S2 Elk1-
VP16 
700 ng - - 200 ng - 100 ng 3 µL 
pGL2- basic 
Elk1-VP16 
700 ng - - 200 ng - 100 ng 3 µL 
*pGL2-S2 construct includes optimal promoter of SPG4 gene 
 Each transfection was performed as triplicates. 
Table 2.26: Transfection content for pGL3-F2 forced experiment. 
Construct name *pGL3-
F2  
wt-
Elk1  
Elk1-
woR  
Elk1-
VP16. 
pCMV-
Myc  
pRL-TK 
Control. 
Transfast 
reagent 
pGL3-F2 700 ng - - - 200 ng 100 ng 3 µL 
pGL3- basic 700 ng - - - 200 ng 100 ng 3 µL 
pGL3-F2 Elk1 700 ng 200 ng - - - 100 ng 3 µL 
pGL3- basic 
Elk1 
700 ng 200 ng - - - 100 ng 3 µL 
pGL3-F2 Elk1-
woR 
700 ng - 200 ng - - 100 ng 3 µL 
pGL3- basic 
Elk1-woR 
700 ng - 200 ng - - 100 ng 3 µL 
pGL3-F2 Elk1-
VP16 
700 ng - - 200 ng - 100 ng 3 µL 
pGL3- basic 
Elk1-VP16 
700 ng - - 200 ng - 100 ng 3 µL 
*pGL3-F2 includes optimal promoter of KATNB1 gene. 
Each transfection was performed as triplicates. 
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2.2.18 Luminometrical measurement 
Genetic reporter system is commonly used in eukaryotic gene expression studies. 
Dual reporters are generally used to improve experimental accuracy. Normalizing the 
activity of the experimental reporter to the activity of the internal control minimizes 
experimental variability caused by differences in cell viability or transfection 
efficiency. Other source of variability, such as in pipetting volumes, cell lysis 
efficiency and assay efficiency can be effectively eliminated. In this study, the Dual-
Luciferase® Reporter (DLR) Assay System from Promega was used. In the DLR 
Assay, the activities of firefly (Photinus pyralis) and Renilla (Renilla reniformis) 
luciferases are measured sequentially from a single sample. Firstly, cells are 
harvested by lysing with 1X Passive Lysis Buffer. This buffer is specifically 
formulated to minimize the low-level autoluminescence emitted by Renilla luciferase 
substrate, coelenterazine. Firstly, the firefly luciferase reporter is measured by adding 
Luciferase Assay Reagent II (LAR II) to generate a stabilized luminescent signal. 
After measurement of firefly, Stop & Glo® Reagent was added into same tube to 
quench firefly luciferase reaction and initiate Renilla luciferase reaction. Stop & 
Glo® Reagent also produces a stabilized signal from the Renilla luciferase, which 
decays slowly over the course the measurement (Promega Technical Manual, 
E1910). 
The luciferase activity depends on the functionally of the promoter upstream from 
luc+; in this study, these promoters are SPG4 and KATNB1 genes promoters. For the 
forced experiments, the luciferase activity depends on functionally of transcription 
factor on the promoter upstream of luc+; in this study these transcription factors are 
Elk1 and its different forms Elk1 without repression domain (Elk1-woR) and 
constitutively active form of Elk1 (Elk1-VP16). 
The chemiluminescence was measured by Fluoroskan Ascent FL luminometre from 
Thermo Electron Corporation. The PMT voltage was default setting which is 845 and 
integration time was chosen to be 10.000. Scaling factor was adjusted to 10 after 
optimization the measurements. At least 1 h before the assay needed amount of the 
LAR II and Stop & Glo® Buffer were taken out from -80 oC and -20 oC refrigators 
respectively to be thawed in room temperature. Then Stop & Glo® Reagent was 
prepared by adding 50X Stop & Glo® Substrate to the Stop & Glo® Buffer to 1X 
final concentration. All transfections were performed as triplicates and were repeated 
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at least two times using different DNA preparations. Cells were prepared to assay 
according to manufacturer instructions, 
 48 h post-transfection, medium was removed from cultured cells, and 60 µL 
1X Passive Lysis Buffer was added to each well. 
 Homogenous lysates was rapidly prepared by manually scraping the cells. 
 The lysate were transferred into microfuge tube for analysis. 
 Luminometer was programmed to perform a 2 sec premeasurement delay 
while shaking the plate, followed by 10 sec measurement period for each 
reporter assay. 
 50 µL of LAR II was added into one well of luminometer plate and then 50 
µL of cell lysate was transferred to the same well. 
 Firefly luciferase luminescence was measured and recorded. 
 50 µL Stop & Glo® Reagent was immediately added to the same well. 
 Renilla luciferase luminescence was measured and recorded. 
 This procedure was repeated for each sample separately.  
2.2.19 PMA treatment 
50.000 cells were plated in each well of 24 well plate and transfected with 
pCMV6.Elk1 in indicated amount in table 2.27. After 18 h of growth, cells were 
serum-starved for 24 h, and then treated with 10 nM PMA for 6 h prior to luciferase 
assays or immunocytochemistry. 
Table 2.27: Transfection content for pGL2-S2 forced experiment under PMA 
treatment condition. 
Construct 
name 
pGL2-S2  wt-Elk1  pCMV-Myc  
pRL-TK 
Control  
Transfast 
reagent 
pGL2-S2 700 ng - 200 ng 100 ng 3 µL 
pGL2- basic 700 ng - 200 ng 100 ng 3 µL 
pGL2-S2 Elk1 700 ng 200 ng - 100 ng 3 µL 
pGL2- basic 
Elk1 
700 ng 200 ng - 100 ng 3 µL 
pGL2-S2 
Elk1-PMA 
700 ng 200 ng - 100 ng 3 µL 
pGL2- basic 
Elk1-PMA 
700 ng 200 ng - 100 ng 3 µL 
Each transfection was performed as duplicates. 
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2.2.20 KCl treatment 
50.000 cells were plated in each well of 24 well plate and transfected with 
pCMV6.Elk1 indicated amount in table 2.28. After 24 h from transfection the cells 
were depolarized by KCl in the medium with addition of 31% depolarization buffer 
(170 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES) at a final concentration 
of 50 mM KCl for 1 hour. When 48 h post transfection process is completed, cells 
were prepared for luciferase measurement, immunocytochemistry or Western 
blotting. 
Table 2.28: Transfection content for pGL3-F2 forced experiment under KCl 
treatment condition. 
Construct 
name 
pGL3-F2  wt-Elk1  pCMV-Myc  
pRL-TK 
Control  
Transfast 
reagent 
pGL3-F2 700 ng - 200 ng 100 ng 3 µL 
pGL3- basic 700 ng - 200 ng 100 ng 3 µL 
pGL3-F2 Elk1 700 ng 200 ng - 100 ng 3 µL 
pGL3- basic 
Elk1 
700 ng 200 ng - 100 ng 3 µL 
pGL3-F2 
Elk1-KCl 
700 ng 200 ng - 100 ng 3 µL 
pGL3- basic 
Elk1- KCl 
700 ng 200 ng - 100 ng 3 µL 
*Each transfection was performed as triplicates. 
2.2.21 Nucleofection 
Nucleofection is a transfection method based on physical method of electroporation 
which enables transfer of nucleic acid into the cells. It employs a non-viral method 
based on an optimized combination of electrical parameters, generated by device 
called Nucleofector, with cell type specific reagents. The substrate is transferred 
directly into both cell nucleus and cytoplasm. In addition the transfection efficiency 
is much higher than traditional methods. Nucleofection procedure is as follow: 
 Cultured cells were lifted and cell number was calculated (section 2.1.16.2), 
1x10
6
 cells for each well of 6 well tissue culture plate were seeded and 
centrifuged 900 rpm for 5 min. 
 Pellet was resuspended carefully with 100 µL room temperature 
Nuclefector® Solution per sample. (Leaving cell in Nuclefector® Solution 
for extended periods of time no longer than 15 min.) 
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 The cell suspension was combined with 8 µg DNA and then cell/DNA 
suspension was transferred into nucleofector cuvette. 
 The appropriate Nucleofector® Program G-004 was selected and cuvette was 
inserted into Nucleofector® Cuvette Holder and the selected program was 
applied by pressing the X-button. 
 The cuvette was taken out of holder once the program was finished. 
 500 µL culture medium was immediately added to cuvette and the sample 
was transferred into the prepared 6 well plate (final volume 2 mL media per 
well). The cells were incubated in 37 
o
C, 5% CO2 incubator until analysis. 
2.2.22 RNA isolation 
RNA isolation was performed using Roche, High Pure RNA Isolation Kit, following 
instructions of the manufacturer. This kit is designed for the purification of total 
RNA from cultured cells. .The protocol of High Pure RNA Isolation Kit, Roche is as 
follows: 
 After 24 h post-nucleofection, cells were detached, collected separately in 
centrifuge tube and centrifuged 900 rpm for 5 min. 
 The pellet was resuspended in 200 µL PBS. 
 400 µL Lysis/Binding Buffer was added into the cell suspension and vortexed 
for 15 sec. 
 The sample was transferred to a High Pure Filter Tube and centrifuged 8.000 
x g for 15 sec. 
 Flow through was discarded and filter tube was combined again. 
 90 µL DNase Incubation Buffer and 10 µL DNaseI were mixed for each 
sample. This mixture was added in filter tube containing sample and 
incubated for 15 min at room temperature. 
 500 µL Wash Buffer I was added into filter tube, centrifuged 8.000 x g for 15 
sec and flow-through was discarded 
 500 µL Wash Buffer II was added into filter tube centrifuged 8.000 x g for 15 
sec and flow-through was discarded. 
 200 µL Wash Buffer II was added into filter tube and centrifuged maximum 
speed (approximately 13.000 x g) for 2 min to remove residual wash buffer. 
 The filter tube was placed into clean 1,5 mL microcentrifuge tube. 
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 50 µL Elution Buffer was added into filter tube to elute RNA and centrifuged 
at 8.000 x g for 1 min. 
 Isolated RNA was stored -80 oC for future experiments. 
2.2.23 cDNA synthesis 
cDNA synthesis was performed by using Thermo Scientific RevertAid H Minus First 
Strand cDNA Synthesis Kit which is a complete system for an efficient synthesis of 
the first strand cDNA from mRNA or total RNA templates. The procedure for cDNA 
synthesis is given bellow: 
 The components given in table 2.29 were mixed gently and spun down. 
 This mixture was incubated at 65 oC for 5 min and the chilled on ice. 
Table 2.29: The first part components of cDNA synthesis reaction. 
Component Amount 
Template RNA 1 µg 
Random Hexamer Primer 1 µL 
Water, nuclease free Up to 12 µL 
 The other components given in table 2.30 were added in mixture, mixed 
gently and spun down. 
Table 2.30: The second part components of cDNA synthesis reaction. 
Component Amount 
5 X Reaction Buffer 4 µL 
RiboLock RNase Inhibitor (20u/ µL) 1 µL 
10 mM dNTP Mix 1 µL 
Reverse Transcriptase (200u/ µL) 
A 
1 µL 
Total Volume 20 mL 
 After addition of second part component, mixture was incubated for 5 min at 
25°C followed by 60 min at 42°C. To terminate the reaction mixture was 
heated at 70°C for 5 min. After reaction cDNA’s were stored -80 oC. 
2.2.24 Real time PCR 
The Real Time PCR (RT-PCR) method is based on PCR, which is used to amplify 
and simultaneously quantify a targeted DNA molecule. The quantity is either an 
absolute number of copies or a relative amount when normalized to DNA input or 
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additional normalizing gene.In this study, specific probes and primers for spastin and 
p80-katanin were purchased from Universal Probe Library (Roche Applied Science 
Url-4), probe number and primers are given table 2.31.  
Table 2.31: Primers and probes for RT-PCR. 
Primer Primer Sequence Probe Number 
Spastin (F) 5’-TTCTGGAGTGAAACAGGGATC-3’ 15 
Spastin (R) 5’-TTTGTCCTATTTGTTTTCGGAG-3’ 
P80-katanin (F) 5’-CGAGCCATCTCAGCTCAATA-3’ 1 
P80-katanin (R) 5’-AATCAAGGCAGGGGATGG-3’ 
Beta-actin (β-actin) (Roche Universal Probe Library Human ACTB Gene Assay) 
gene was used as reference for RT-PCR studies. RT-PCR reaction was performed 
with Light Cycler® 480 Probes Master RT-PCR Kit using a Roche Light Cycler 480 
according to the following Light Cycler program given in table 2.32. 
Table 2.32: Real Time PCR Program. 
Step Temperature Time Cycle 
Initial Denaturation 95 oC 10 min 
 
1 
Denaturation 95 oC 10 sec 
45 
Amplification 60 oC 30 sec 
Extension 72 oC 1 sec 
ΔΔCt method was used to analyze RT-PCR results. According to Schmittgen T.D. et 
al, efficiency rate for each gene should be between 1,8-2,2  and error rate should be 
below 0,2 to be able to use ΔΔCt method. Therefore, error rate and efficiency values 
for each gene were determined and all of them were in expected ranges. 
2.2.25 Immunostaining 
Immunostaining is a biochemical technique used to visualize proteins in the cell. The 
primary antibodies which are specific for the intended protein, and secondary 
antibodies which are specific for the IgG heavy and light chains of the primary 
antibody are used. Detection is usually performed by fluorescence. 
 SH-SY5Y cells (3x104) were seeded on poly-L-lysine coated coverslips and 
transfected as described in section 2.2.17. 
 48 h post-transfection, culture medium was removed. Cells were washed 2 
times with PBS 
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 Cells were fixed in prechilled methanol and incubated 15 min at -20 oC. 
 Cells were washed 3 times with PBS 
 Blocking solution was prepared 10% antibody specific serum, 10 mg/mL 
bovine serum albumin (BSA) and PBS; cells were blocked with blocking 
solution 1 h at room temperature. 
 Primary antibodies were diluted in PBS (1:500 Rabbit polyclonal anti-Elk1, 
1:200 Mouse monoclonal anti-spastin, 1:250 Goat polyclonal anti-katanin 
antibodies)  
 Cells were incubated with 300 µL antibody solution/coverslip overnight 4oC. 
 Following day primary antibodies were removed and cells were washed 3 
times with PBS. 
 Cells were blocked with blocking solution 1 h at room temperature. 
 Secondary antibodies were diluted with PBS (1:1000 both Alexa Fluor® 647 
goat anti-mouse, 488 goat anti-rabbit Alexa Flour® and donkey 488 anti-goat 
Alexa Flour®) and cells were treated with secondary antibody solution for 1 
h at 37°C in dark. 
 Cells were washed 1 time for 5 min with PBS 
 Cells were incubated 1:1000 diluted DAPI for 5 min and then washed 3 times 
with PBS 
 10 µL mounting medium was added into slides. 
 Coverslips were put onto object slide and fixed by using nail polisher.  
 Samples were visualize and analyzed by using with Leica TCS SP2 SE 
Confocal Microscope with appropriate laser beams and photos were taken 
under 63 X magnification. 
2.2.26 Total protein isolation 
Total protein isolation from cells was performed by using ROCHE, cOmplete Lysis-
M Kit. Procedure of protein isolation is as follow: 
 1x106 cells were seeded each well of 6 well plate and transfected as described 
in section 2.2.17. 
 After 48 h transfection, one complete-M Mini tablet was dissolved in 10 mL 
Lysis-M Reagent to prepare working solution. 
 Culture media was removed and cells were washed with PBS. 
55 
 
 200 µL Lysis- M Reagent solution was added to each well and incubated for 
5 min at room temperature. 
 The cell lysates were collected and transferred to a microcentrifuge tube. 
 The lysate was centrifuged at 14.000 x g for 5-10 min. 
 The supernatant containing soluble protein was transferred to clean tube and 
was stored -80 °C. 
2.2.27 BCA Assay 
The bicinchoninic acid (BCA) assay was performed by using Pierce Micro BCA™ 
Protein Assay Reagent Kit to determine the protein concentration. BCA a detection 
reagent for Cu
+1, 
which is formed when Cu
+2
 is reduced by protein in an alkaline 
environment, is utilized. A purple-colored reaction product is formed by the 
chelation of two molecules of BCA with one cuprous ion (Cu
+1
). This complex 
exhibits a strong absorbance at 562 nm. The procedure for BCA assay is as follows: 
 The different diluted Albumin (BSA) standard solutions were prepared 
between 0-400 µg/mL range (0 µg/mL- 3,125 µg/mL-6,25µg/mL- 12,5 
µg/mL- 25 µg/mL- 50 µg/mL- 100 µg/mL- 200 µg/mL- 400 µg/mL). 
 fresh working reagent (WR) was prepared by mixing 25 parts of Micro 
BCA™ Reagent MA and 24 parts Reagent MB with 1 part of Reagent MC 
(25:24:1, Reagent MA:MB:MC). 
 Each sample was diluted 1:20 ratio and 100 µL diluted samples and standard 
solution duplicate were put into microplate wells. 
 100 µL WR was added into each well and mixed plate thoroughly on a plate 
shaker for 30 sec. 
 Microplate was incubated at 37°C for 2 h. 
 After incubation absorbance was measured at 562 nm on plate reader. 
2.2.28 SDS-polyacrylamide gel electrophoresis of proteins (SDS-PAGE) 
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis is a technique 
widely used to separate proteins according to electrophoretic mobility. In this 
method, tertiary structure of proteins is disrupted by SDS and reducing agents such 
as β-mercaptoethanol. The proteins are separated in gel according to their size. 
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In this study, Fluka SDS Preparation Kit is used for preparation both 5% stacking gel 
and 10 % separating gel whose contents were given in table 2.33 and table 2.34 
respectively. 
Table 2.33: Content of 5% stacking gel. 
Contents Volume 
Stacking acrylamide 0,25 ml 
Gel buffer 0,75 ml 
dH2O 2 ml 
10% APS 20 µl 
TEMED 2 µl 
Table 2.34: Content of 10% separating gel 
Contents Volume 
50% glycerol 2 ml 
Separating acrylamide 1,22 ml 
Gel buffer 2 ml 
dH2O 0,78 ml 
10 % APS 75 µl 
TEMED 7,5 µl 
 Prepared gels were poured between SDS-glasses and left for polymerization. 
 After gel polymerized, samples, that were mixed 5X SDS-loading dye and 
boiled 95 °C for 5 min to gain primary structure, were loaded in equal 
concentration into wells. 
 The gel was placed into tank and run in running buffer at 25 mA for 2 h. 
2.2.29 Western blotting 
Western blot is used to detect specific proteins. After separation of denatured 
proteins according to size by SDS-PAGE, the proteins are transferred to 
nitrocellulose membrane where they are labeled using antibodies specific to the 
target protein. 
 After SDS-PAGE, gel was taken from the tank and between glasses. 
 Nitrocellulose membrane and 2 filter papers were put into towbin 
electrotransfer buffer for 10 min for equilibration 
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 After equilibration, the sandwich was prepared between filter papers and 
nitrocellulose membrane. 
 The gel was put on the membrane with care not to disrupt the gel. Air bubbles 
were removed. 
 The protein transfer was carried out in semi-dry blotting apparatus for 20 V 
for 30 min at 4 °C. 
 Then the membrane was blocked with blocking solution to prevent non-
specific binding to empty regions on the membrane. In other words, efficient 
blocking simply reduces the background. 
 After blocking, the membrane was incubated with 1:500 diluted with 
blocking solution primary antibody  (Rabbit polyclonal SUMO2-3, rabbit 
polyclonal Elk1, mouse monoclonal spastin, rabbit polyclonal katanin or 
mouse monoclonal β-actin antibody) for overnight at 4 °C with gentle 
shaking. 
 Following day membrane was washed with TBS-T buffer for 5 min 6 times 
with gentle shaking 
 1:5000 diluted secondary antibody was prepared in blocking solution. 
 The membrane was incubated with secondary antibody for 1 h at room 
temperature with gently shaking. 
 The membrane was washed for 5 min 6 times with gentle shaking. 
 For detection, 20X LumiGLO® Reagent or SuperSignal® West Femto 
Maximum Sensitivity Substrate was used according to manufacturer 
instructions. The membrane was exposed to X-ray film for particularly time 
and then developed in Kodak Medical X-ray Processor according to 
manufacturer’s instruction. 
2.2.30 Immunoprecipitation 
The cell extracts were treated with specific antibody in order to concentrate target 
proteins. 
 Dynabeads were resuspended in the solution via vortex for 30 sec. 
 50 μl (1,5 mg) beads were transferred into microcentrifuge tube and placed on 
magnet. The magnet provides separation of beads from solution. 
 After beads were separated, supernatant was removed. 
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 Rabbit polyclonal Elk1 antibody was diluted in 1:50 μg/μl in PBST buffer 
and diluted antibody solution was added to prepared beads. 
 This mixture was incubated with rotation at room temperature for 10 min. 
 The beads were separated via magnet, supernatant was removed. 
 Bead-antibody complex was treated with PBST by pipetting gently and 
washed. 
 The beads were separated via magnet again. 
 ~1 mg cell extracts of samples were added into tubes.  
 Mixture was resuspended and incubated with rotation for 10 min at room 
temperature.  
 Bead-antibody-antigen complex was washed 3 times with 200 µl PBS. 
  Elk-1 proteins bound with Elk-1 antibodies onto the beads were eluted using 
20 μl elution buffer. 
 The tubes were incubated for 10 min at 70 °C in order to dissociate the 
complex. 
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3. RESULTS AND DISCUSSION 
3.1 Production of Elk1 without R domain constructs 
Both upstream between (1-669 bases) and downstream sequences (between 831-1287 
bases) of WT-Elk1 were amplified with PCR respectively using primers shown in 
table 2.14. The PCR products were run on agarose gel and expected DNA fragments 
were observed. The fragments are shown in figure 3.1 in the presence of Fermentas 
Mass Ruler Mix DNA Marker. 
 
Figure 3.1: (a) Schematic illustration of Elk1. (b)Agarose gel images of PCR 
products.  2
nd
 lane is the upstream fragment of R domain and 3
rd 
line is 
the downstream fragment of R domain. 
Amplified PCR products of upstream region of R domain and pCVM6 vector were 
digested by Fermentas’s KpnI and SalI restriction enzymes. After digestion and 
purification by QIAGEN QIAquick PCR Purification Kit, ligation step was 
performed with Roche T4 DNA Ligase. Subsequently, ligation mixture was 
transformed into CaCl2 treated E.coli DH5α competent cells. When the colonies 
appeared, colony PCR was performed in order to verify whether the colonies contain 
the plasmid of interest. PCR fragments are shown in figure 3.2 in the presence 
Fermentas Mass Ruler Mix DNA Marker.  
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Figure 3.2: Agarose gel image of colony PCR fragments of upstream region of R 
domain. 
Then this construct including upstream of R domain sequence was digested with 
Fermentas’s SalI and BamHI restriction enzymes. Purification and ligation to 
restricted vector and PCR product were performed with using QIAquick PCR 
Purification Kit and T4 ligase. The ligation mixture was transformed into E.coli 
DH5α competent cells and colony PCR was performed for verification. PCR 
fragments are shown in figure 3.3 in the presence of Fermentas Mass Ruler Mix 
DNA Marker.  
 
Figure 3.3: Agarose gel image of colony PCR fragments containing upstream and 
downstream region of R domain. 
Plasmid DNA was isolated from colony PCR positive colony with QIAGEN’s 
Qiaprep Spin Miniprep Plasmid Isolation Kit. 
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3.2 Sequence Alignment Analysis of Constructed Plasmid 
Sequence analysis of constructed plasmid was performed via EBI Clustalw sequence 
analysis tool in order to verify the accuracy of the inserts. It is found that constructs 
did not contain any mutation. After confirmation, construct was transformed with 
E.coli dam-/dcm-, and produced large scale by QIAGEN EndoFree Plasmid Maxi 
Kit. 
3.3 Results for Spastin Optimal Promoter 
3.3.1 Luminometrical measurement data of forced experiments for spastin 
promoter 
In order to determine of Elk1 and Elk1.woR which is not contain repression domain 
and cannot be SUMOylated, SH-SY5Y neuroblastoma cells were transfected with S2 
construct containing spastin optimal promoter, and co-transfected with both S2 and 
WT-Elk1 (pCMV6.Elk1), or Elk1 without R domain (pCMV6.Elk1.woR), or 
constitutively active form of Elk1 (pCMV6.Elk1.VP16) expression vectors 
respectively. Each transfection was performed as triplicate and experiments were 
repeated 3 times on separate days. Forced experiment, which is co-transfection of 
cells with promoter and transcription factor, results are indicated table 3.1, table 3.2 
and table 3.3. Average of all experiment and graph are shown table 3.4 and figure 3.3 
respectively. 
Table 3.1: Measured light units of experiment n=1 for spastin promoter. 
N=1 S2 
S2 
Basic 
WT.Elk1 
WT.Elk1 
Basic 
Elk.woR 
Elk.woR 
Basic 
Elk.VP16 
Elk.VP16 
Basic 
1 
Firefly 123,4 1,224 21,96 0,5818 13,48 0,3881 245,8 3,004 
Renilla 219,5 103,1 670,1 386,2 217,7 231,9 352,9 324,5 
2 
Firefly 141,3 1,236 23,4 0,5957 11,43 0,2936 257,1 4,127 
Renilla 231,4 90,21 739,8 402,6 199,7 185 397,6 393,2 
3 
Firefly 199,4 1,375 21,33 0,5419 9,506 0,3484 236,4 3,216 
Renilla 335,7 106,3 614,9 380,3 177,4 189,4 356,7 367,4 
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Table 3.2: Measured light units of experiment n=2 for spastin promoter. 
N=2 S2 
S2 
Basic 
WT.Elk1 
WT.Elk1 
Basic 
Elk.woR 
Elk.woR 
Basic 
Elk.VP16 
Elk.VP16 
Basic 
1 
Firefly 111,6 1,261 22,9 1,058 12,06 0,4093 200,1 3,18 
Renilla 191,8 132,8 660,2 658,4 161,4 158,6 300,5 263,7 
2 
Firefly 141,5 2,592 29,25 1,202 11,82 0,4065 190,1 2,809 
Renilla 202 189,4 890,6 637,9 163,5 162 279,9 253,4 
3 
Firefly 158,9 2,271 22,04 1,103 14,91 0,4482 185,4 3,143 
Renilla 203,4 193,3 701,7 623,3 204,9 154,9 267,9 254,8 
Table 3.3: Measured light units of experiment n=3 for spastin promoter. 
N=3 S2 
S2 
Basic 
WT.Elk1 
WT.Elk1 
Basic 
Elk.woR 
Elk.woR 
Basic 
Elk.VP16 
Elk.VP16 
Basic 
1 
Firefly 188,1 2,221 21,56 1,192 17,28 0,667 239,4 3,897 
Renilla 215,3 183,5 1162 248,1 267,4 156,1 425,4 491,2 
2 
Firefly 203,1 2,773 25,4 1,327 18,97 0,6246 276,2 3,652 
Renilla 234,4 245,3 1156 296,1 331,6 164,8 493,3 464,2 
3 
Firefly 205,2 2,288 20,24 1,17 22,11 0,6326 294,4 3,292 
Renilla 225,8 218,1 1286 303,1 381,8 162,9 496,3 441,7 
The following equation is used to determine the normalized fold change in activity 
between test groups, considered as fold of induction in respect to the activity of the 
empty vector pGL2-Basic. The calculated fold activity and graph representing the 
obtained data are given in the table 3.4 and figure 3.4 below.    
                             (3.1) 
 
Table 3.4: Average of calculated F/R of all experiments and standard deviation for 
spastin promoter. 
Experiment F/R pGL2-S2 WT.Elk1 Elk1.woR Elk1.VP16 
N=1 45,8808 22,464 33,8702 70,36554 
N=2 59,0783 18,8066 27,5297 57,98677 
N=3 78,1417 4,2799 15,0456 73,78774 
Average F/R 61,0337 15,1836 25,6069 67,4027 
Average F/R Standard 
Deviation 
16,2191 9,61826 9,74324 8,5454 
Δ Fold Activation 1 0,24877 0,4175 1,10398 
  
= 
_______________________________ 
   Average (Firefly/Renilla) pGL2-Basic 
Average (Firefly/Renilla) Sample X 
Δ Fold Activation 
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Figure 3.4: Average fold activities of Elk1, Elk1.woR and Elk1.VP16 forced 
experiment on SPG4 optimal promoter. 
According to forced experiments, WT-Elk1 has repressor activity on SPG4 optimal 
promoter, Elk1.woR reversed the repressive activity of WT-Elk1, and Elk1.VP16 
increased the promoter activity, as expected as it is the constitutively active form of 
Elk1. However, the rise in the promoter activity by Elk1.woR was not as high as the 
unforced promoter activity. Elk1 has also another repression domain coinciding with 
the ETS DNA binding domain. Transcriptional repression of Elk1 through this 
domain involves the recruitment of co-repressor complexes such as mSin3A-HDAC 
complex that possess histone deacetylase activity (Yang et al., 2001).   
Another  mechanism underlying this phenomenon might be that SENP1 
(SUMO1/sentrin-specific protease 1), which impairs SUMO modifications on target 
proteins, can act as co-activator or recruit co-activators to the target protein while 
interacting with its target and to do this it might require SUMO modification on 
target protein. One of the previous study strengthening our speculation demonstrated 
that SUMO deficient mutant Elk1 could not provide expression of target gene as 
control cells in the absence of SENP1(Witty et al., 2010).  
3.3.2 mRNA expression level of SPG4 gene  
To confirm expressional results of Elk1.woR regulation on spastin mRNA level in 
SH-SY5Y cells, qRT-PCR analysis was performed. β-actin gene was used as 
reference for qRT-PCR studies. The values were calculated according to ∆∆Ct 
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method (Schmittgen  et al., 2008). qRT-PCR results are shown in table 3.5,  table 3.6 
and figure 3.5. 
Table 3.5: Ct value of experiment n=1 for spastin promoter. 
N=1 β-actin spastin  β-actin spastin  β-actin spastin 
WT.Elk1 16,23 21,33 Elk1.woR 21,82 27,68 Elk1.VP16 18,12 25,43 
 17,41 21,83  22,62 27,51  16,71 23,62 
Negative 19,12 26,44 Negative 19,12 26,44 Negative 19,12 26,44 
 19,4 26,86  19,4 26,86  19,4 26,86 
Table 3.6: Ct value of experiment n=2 for spastin promoter. 
N=2 β-actin spastin  β-actin spastin  β-actin spastin 
WT.Elk1 
28,48 25,89 
Elk1.woR 
22,58 23,02 
Elk1.VP16 
23,84 26,71 
 
28,72 24,51 
 
23,16 23,68 
 
23,23 26,17 
Negative 
22,17 23,63 
Negative 
22,17 23,63 
Negative 
22,17 23,63 
 
22,39 24,27 
 
22,39 24,27 
 
22,39 24,27 
∆Ct=  2^ - (Target gene - Reference gene) 
∆∆Ct= 2^- (Sample ∆Ct - Control ∆Ct)                (3.2) 
 
Figure 3.5: ΔΔCt values of mRNA expression levels of SPG4 gene of WT.Elk1,    
Elk1.woR and Elk1.VP16 transfected SH-SY5Y neuroblastoma cells. 
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It is suggested that SUMOylation of R domain on Elk1 could also decrease mRNA 
level of spastin by repressing SPG4 promoter activity that does not allow futher 
transcription of spastin. 
3.3.3 Luminometrical measurement data of forced experiment under PMA 
treatment condition for spastin promoter 
In order to verify that SUMO-modified Elk1 has repressor role on SGP4 promoter, 
effect of de-SUMOylated Elk1 on SPG4 promoter was analyzed by using a reverse 
perspective. SH-SY5Y neuroblastoma cells were transfected with S2 construct and 
co-transfected with both S2 and WT-Elk1 (pCMV6.Elk1). After transfection, 
phorbol 12-myristate 13-acetate (PMA) was added into the medium .The reason of 
PMA treatment was that PMA is a mitogenic agent and promotes phosphorylation of 
Elk. The serum starved cells were exposed to PMA for 6 h and luciferase assay was 
performed. Each transfection was performed as triplicates at the same time and 
experiments were repeated 2 times on separate days. The data of this experiment is 
shown below. 
Table 3.7: Measured light units of experiment n=1for PMA treatment. 
N=1 S2 S2 Basic WT.Elk1 
WT.Elk1 
Basic 
WT.Elk1 
PMA 
WT.Elk1  
PMA Basic 
1 
Firefly 
123,4 1,224 21,96 0,5818 13,48 0,3881 
Renilla 
219,5 103,1 670,1 386,2 217,7 231,9 
2 
Firefly 
141,3 1,236 23,4 0,5957 11,43 0,2936 
Renilla 
231,4 90,21 739,8 402,6 199,7 185 
3 
Firefly 
199,4 1,375 21,33 0,5419 9,506 0,3484 
Renilla 
335,7 106,3 614,9 380,3 177,4 189,4 
Table 3.8: Measured light units of experiment n=2for PMA treatment. 
N=2 S2 S2 Basic WT.Elk1 
WT.Elk1 
Basic 
WT.Elk1 
PMA 
WT.Elk1 
PMA Basic 
1 
Firefly 
0,2336 0,0045 0,0867 0,0019 0,0707 0,0026 
Renilla 
1,346 1,162 1,336 1,529 1,023 1,665 
2 
Firefly 
0,1743 0,005 0,079 0,0061 0,0845 0,0055 
Renilla 
1,674 0,943 1,12 1,054 1,632 1,224 
3 
Firefly 
0,1962 0,0057 0,0746 0,0041 0,0861 0,0027 
Renilla 
1,477 1,058 1,225 1,395 1,362 1,246 
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The 3.1 equation is used to determine the normalized fold activation between test 
groups, considered as fold of induction in respect to the activity of the empty vector 
pGL2-Basic. The calculated fold activity and graph are given below. 
Table 3.9: Average of calculated F/R of PMA treatment experiments and standard 
deviation. 
Experiment F/R pGL2-S2 WT.Elk1 WT.Elk1+PMA 
N=1 28,1897 19,6935 32,9182 
N=2 29,2753 15,0127 30,7919 
Average F/R 28,7325 17,3531 31,8550 
Average F/R Standard 
Deviation 
4,8602 3,0350 4,7540 
Δ Fold Activation 1 0,6039 1,1086 
 
 
Figure 3.6: Average fold activities of WT.Elk1 forced experiment with PMA 
treatment on SPG4 optimal promoter. 
According to these results, repressive effect of Elk1 on SPG4 promoter was reversed 
in PMA treated cells. It was shown that PMA can activate MAPK pathway by 
inducing phosphorylation and thus would cause phosphorylation of Elk1 (Hu et al., 
2000). PMA also causes deSUMOylation of Elk1 (Witty et al., 2010). These data 
confirmed that SUMOylated Elk1 represses SPG4 gene expression and activation of 
MAPK pathway results in loss of SUMO modification of Elk1 and thus, leads to 
transcriptional activation of Elk1. 
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3.3.4 Immunocytochemistry analysis of endogen spastin 
After qRT-PCR and forced promoter activity experiment, protein level was obtained 
by using immunocytochemistry technique. The effects of Elk1-woR overexpression 
and PMA treatment were analyzed on the level of endogenous spastin protein. 
Firstly, SH-SY5Y cells were transfected with wt-Elk1, Elk1-woR or Elk1-VP16 
expressing vector and after 48 h incubation, to confirm the overexpression of Elk1, 
Elk1-woR and Elk1-VP16 and spastin protein level, cells were immunostained with 
rabbit anti-Elk1 polyclonal and mouse anti-spastin monoclonal antibodies as 
primary, and goat 488 anti-rabbit and goat 647 anti-mouse Alexa Flour® antibody, as 
secondary antibodies, respectively. Then, Elk1-woR and Elk1-VP16 overexpressed 
cells were compared to wt-Elk1 transfected cells (Figure 3.7). 
 
Figure 3.7: The images of immunostained Elk1 constructs (green) and endogen 
spastin (red). 
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When Elk1-woR and Elk1.VP16 transfected cells were compared to wt-Elk1 
overexpressed cells, spastin level increased in Elk1-woR and Elk1-VP16 
overexpressed cells. Moreover wt-Elk1 transfected cells had less spastin protein 
compared to control cells. 
Additionally, SH-SY5Y cells were transfected with wt-Elk1 expression vector. After 
18 h growth, cells were serum-starved for 24 h, and then one wt-Elk1 transfected 
sample was treated with 10 nM PMA. After incubation, cells were immunostained 
with rabbit anti-Elk1 polyclonal and mouse anti-spastin monoclonal antibodies as 
primary, and goat 488 anti-rabbit and goat 647 anti-mouse Alexa Flour® antibodies, 
as secondary antibodies, respectively (Figure 3.8).  
 
Figure 3.8: The images of immunostained Elk1 (green) and endogen spastin (red) 
under PMA treatment condition. 
When wt-Elk1 overexpressed and PMA treated cells were compared to Elk1 
overexpressed and untreated cells, an increase in spastin protein level was observed. 
On the other hand, spastin protein level in wt-Elk1 transfected cells was less than 
untransfected control cells, indicating wt-Elk1 transcription factor indeed reduced the 
spastin level. These immunostaining experiments are consistent with other 
experiments in expression and transcription level of spastin. 
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3.4 Results for p80-Katanin Optimal Promoter 
3.4.1 Luminometrical measurement data of forced experiments for p80-katanin 
promoter 
In order to determine effect of Elk1 on KATNB1 optimal promoter, SH-SY5Y 
neuroblastoma cells were transfected with F2 construct including p80-katanin 
optimal promoter, and co-transfected with both F2 and WT-Elk1 (pCMV6.Elk1) or 
constitutively active form of Elk1 (pCMV6.Elk1.VP16) expressing vectors 
respectively. For statistical analysis each transfection was performed as triplicates at 
the same time and experiments were repeated 3 times on separate days. Results of 
forced experiment are indicated table 3.10, table 3.11 and table 3.12.  
Table 3.10: Measured light units of experiment n=1for p80-katanin promoter. 
N=1 F2 F2 Basic WT.Elk1 
WT.Elk1 
Basic 
Elk1.VP16 
Elk1.VP16 
Basic 
1 
Firefly 20,46 0,5058 7,08 0,1016 37,97 0,2466 
Renilla 2,086 2,997 1,23 1,925 0,7335 1,347 
2 
Firefly 21,45 0,482 8,715 0,085 45,94 0,2823 
Renilla 2,272 2,573 1,159 1,691 0,9139 1,37 
3 
Firefly 23,38 0,6229 7,968 0,0648 48,53 0,2316 
Renilla 2,098 2,723 1,576 1,39 1,128 1,38 
Table 3.11: Measured light units of experiment n=2 for p80-katanin promoter. 
N=2 F2 F2 Basic WT.Elk1 
WT.Elk1 
Basic 
Elk1.VP16 
Elk1.VP16 
Basic 
1 
Firefly 19,18 0,4713 2,893 0,0752 45,49 0,3995 
Renilla 2,75 3,353 0,3843 1,568 0,884 2,218 
2 
Firefly 20,11 0,5122 3,083 0,0792 44,91 0,3225 
Renilla 3,132 3,485 0,5018 1,563 0,9768 1,653 
3 
Firefly 18,25 0,5298 3,085 0,0566 50,13 0,3207 
Renilla 2,714 4,053 0,4999 1,272 1,009 1,726 
Table 3.12: Measured light units of experiment n=3 for p80-katanin promoter. 
N=3 F2 F2 Basic WT.Elk1 
WT.Elk1 
Basic 
Elk1.VP16 
Elk1.VP16 
Basic 
1 
Firefly 6,095 0,2618 5,72 0,0574 25,64 0,1757 
Renilla 1,487 2,392 2,563 2,168 0,8425 0,9982 
2 
Firefly 7,796 0,2755 5,114 0,0577 23,97 0,1986 
Renilla 1,821 2,841 1,647 1,953 0,9057 0,8273 
3 
Firefly 6,055 0,2578 5,348 0,0559 19,79 0,1789 
Renilla 1,84 2,421 1,817 2,35 0,6386 1,225 
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The 3.1 equation is used to determine the normalized fold change in activity between 
test groups, considered as fold of induction in respect to the activity of the empty 
vector pGL3-Basic. Average of all experiment and graph are shown table 3.13 and 
figure 3.9 respectively. 
Table 3.13: Average of calculated F/R of all experiments and standard deviation for 
p80-katanin promoter. 
Experiment F/R pGL3-F2 WT.Elk1 Elk1.VP16 
N=1 
51,9671 122,4833 260,4444 
N=2 
48,1044 138,6389 262,2333 
N=3 
37,2980 103,7510 156,3532 
Average F/R 
45,7898 121,6244 226,3437 
Average F/R Standard 
Deviation 
7,4844 23,1415 54,8993 
Δ Fold Activation 
1 2,6561 4,9430 
 
Figure 3.9: Average fold activities of Elk1 and Elk1.VP16 forced experiment on 
KATNB1 optimal promoter. 
Comparing the luciferase data of F2 construct, Elk1 significantly enhanced the 
optimal promoter activity and as expected constitutively active form Elk1.VP16 
increased gene expression. 
These results show that Elk1 has role as an activator role on regulation of KATNB1 
gene expression. Moreover Elk1 might not be SUMOylated, but phosphorylated by 
MAPK pathway to gain activator capability in by contrast to spastin gene regulation. 
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3.3.2 mRNA expression level of KATNB1 gene  
qRT-PCR was performed  in order to further quantify whether these changes were 
reflected at mRNA level of p80-katanin. Total mRNA was isolated from SH-SY5Y 
cells nucleofected with pCMV.Elk1. β-actin gene was used as reference again. 
Following qRT-PCR experiments, values were calculated according to ∆∆Ct method 
(Schmittgen  et al., 2008). qRT-PCR results are shown in table 3.14 and figure 3.10. 
Table 3.14: Ct value of experiment n=1. 
N=1 β-actin katanin 
 
N=2 β-actin katanin 
WT.Elk1 17,29 27,98 WT.Elk1 19,42 29,1 
 17,91 27,93  18,65 29,22 
Negative 18,81 27,87 Negative 19,86 28,86 
 18,78 28,07  19,28 29,06 
 
Figure 3.10: ΔΔCt values of mRNA expression levels of KATNB1 gene of WT.Elk1,    
transfected SH-SY5Y neuroblastoma cells. 
mRNA levels of human p80-katanin was increased by overexpression of wt.Elk1 in 
SH-SY5Y cells. 
The opposite effect of Elk1 on spastin and p80-katanin promoter might result from 
interaction with SRF. Elk1 has the ability to form ternary complex with SRF and 
SRE (Vickers et al., 2004). This complex formation might be responsible for Elk1 
deSUMOylation and activation of KATNB1 promoter because it has a SRE consensus 
sequence CC(A/T)6GG at position from -515 to -506 juxtaposition of Elk1 binding 
site. (Appendix A) On the other hand, SPG4 optimal promoter does not have this 
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SRE sequence. Therefore Elk1 might not form ternary complex and be 
deSUMOylated. Consequently the absence of SRE on SPG4 promoter may cause the 
repressive effect of Elk. 
3.4.3 Luminometrical measurement data of forced experiment under KCl 
treatment condition for p80-katanin promoter 
A previous study demonstrated that KCl treatment promotes SUMO conjugation (Lu 
et al, 2009). Based on this study, cells were treated with KCl to increase Elk1 
SUMOylation in order to understand whether Elk1 increased the promoter activity by 
MAPK pathway. Cells were transfected with F2 construct and co-transected with F2 
and WT.Elk1 constructs. 24 h after transfection, Elk1 transfected cells were 
incubated in medium containing 50µM KCl for 1 h. Following 48 h post-
transfection, luminometrical measurement is evaluated. Each transfection was 
performed as triplicates at the same time and experiments were repeated 3 times on 
separate days. The data of this experiment is below. 
Table 3.15: Measured light units of experiment n=1for KCl treatment. 
N=1 F2 F2 Basic WT.Elk1 
WT.Elk1 
Basic 
WT.Elk1 
KCl 
WT.Elk1 
KCl Basic 
1 Firefly 4,529 0,1483 1,835 0,0544 2,458 0,0521 
Renilla 0,6542 0,7071 0,755 0,7251 0,7523 1,089 
2 Firefly 4,107 0,0975 2,264 0,0328 2,337 0,0512 
Renilla 0,7085 0,7521 0,7084 0,6967 0,7284 0,7773 
3 Firefly 4,456 0,067 2,411 0,0273 2,513 0,0529 
Renilla 0,9471 0,8388 1,192 0,7582 0,8025 0,5095 
Table 3.16: Measured light units of experiment n=2for KCl treatment. 
N=2 F2 F2 Basic WT.Elk1 
WT.Elk1 
Basic 
WT.Elk1 
KCl 
WT.Elk1 
KCl Basic 
1 Firefly 4,437 0,064 2,104 0,0401 2,866 0,0542 
Renilla 0,6306 0,602 0,5944 0,5721 0,6007 0,6046 
2 Firefly 4,227 0,0563 2,257 0,0386 2,66 0,0265 
Renilla 0,6762 0,6845 0,5899 0,7709 0,9208 0,3239 
3 Firefly 4,568 0,0855 2,643 0,0252 2,885 0,0244 
Renilla 0,6397 0,5458 0,7383 0,6877 0,7313 0,3275 
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Table 3.17: Measured light units of experiment n=3 for KCl treatment. 
N=3 F2 F2 Basic WT.Elk1 
WT.Elk1 
Basic 
WT.Elk1 
KCl 
WT.Elk1 
KCl Basic 
1 
Firefly 3,807 0,0859 1,803 0,0423 2,213 0,0338 
Renilla 0,5599 0,7723 0,8703 1,065 0,6137 0,609 
2 
Firefly 3,406 0,1055 1,875 0,0201 2,066 0,0428 
Renilla 0,6294 0,6804 0,6867 0,8021 0,7018 0,4815 
3 
Firefly 4,075 0,0938 1,979 0,0258 2,421 0,031 
Renilla 0,5376 0,9706 0,5857 0,8698 0,7093 0,4338 
The 3.1 equation is used to determine the normalized fold activation between test 
groups, considered as fold of induction in respect to the activity of the empty vector 
pGL3-Basic. The calculated fold activity and graph are given in the table 3.18 and 
figure 3.11. 
Table 3.18: Average of calculated F/R of KCl treatment experiments and standard 
deviation. 
Experiment F/R pGL3-F2 WT.Elk1 WT.Elk1+KCl 
N=1 41,5620 61,3749 44,1631 
N=2 59,1754 69,8027 47,1811 
N=3 54,5319 99,6689 46,1571 
Average F/R 51,7564 76,9489 45,8338 
Average F/R Standard 
Deviation 
10,1646 22,3592 6,3792 
Δ Fold Activation 1 1,4867 0,8855 
 
Figure 3.11: Average fold activities of WT.Elk1 forced experiment with KCl 
treatment on KATNB1 optimal promoter. 
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According to these results, KCl treated samples show less promoter activity. Elk1 
cannot be phosphorylated by MAPK pathway due to KCl increase of SUMO 
conjugation. Therefore KCl treated and SUMOylated Elk1 cannot increase 
expression of p80-katanin gene as much as untreated Elk1. 
3.4.4 Immunocytochemistry analysis of endogen p80-katanin 
The protein expression level of p80-katanin was analyzed by immunocytochemistry. 
SH-SY5Y cells were transfected with Elk1 expressing vector and after 48 h 
incubation cells were immunostained with goat anti-katanin p80 polyclonal antibody 
as primary antibody and donkey 488 anti-goat Alexa Flour® antibodies as secondary 
antibodies to visualize the levels of p80-katanin protein. Then Elk1 overexpressed 
cell, and both KCl treated and Elk1 transfected cells were compared to the control 
cells (Figure 3.12). 
 
Figure 3.12:  The images of endogenous p80-katanin protein. (a) Elk1 overexpressed 
and untreated cells. (b) Elk1 overexpressed and KCl treated cells. (c) 
Control cells. All of them p80-katanin were stained in green. All blue 
staining (DAPI) represented nucleus of the cells. 
KCl treated and Elk1 over-expressed cells contained lower p80-katanin levels while 
untreated Elk1 over-expressed cells had an increased level of p80-katanin compared 
with the negative control. These results indicated that Elk1 increased the intrinsic 
p80-katanin protein levels, while KCl treatment reversed the Elk1’s activator effects 
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on p80-katanin protein expression. This data showed that KCl addition trigger 
SUMO conjugation and lead Elk1 to repress the expression of endogenous p80-
katanin protein in SH-SYSY cells.  
3.4.5 Western blot analysis of p80-katanin and SUMOylated Elk1 
The protein level of p80-katanin also was analyzed by Western blotting. One group 
of Elk1 transfected cells and one group of untransfected control cells were treated 
with KCl for 1 h. After total protein was isolated, p80-katanin level was analyzed by 
Western blotting. p80-katanin was detected with specific antibody. Then stripped 
membrane was used for the second time for detection of β-actin for normalization of 
bands density. p80-katanin has 80 kDa molecular weight while, β-actin has 41.7 kDa 
(Figure 3.13). 
 
Figure 3.13: The level of p80-katanin and β-actin.  
Western blot image was analyzed by Photoshop software in terms of density of bands 
and results were normalized against β-actin (Figure 3.14). 
 
Figure 3.14: Normalized histogram showing p80-katanin level. 
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Figure 3.14 demonstrates that p80-katanin amount reaches highest level in Elk1 
overexpressing cells. On the other hand KCl treated cells decreased p80-katanin 
expression both in Elk1transfected and untransfected cells. 
After Elk1 was eluted from total protein of KCl treated and untreated cells by using 
immunoprecipitation technique, SUMO proteins were determined with specific 
SUMO1 and SUMO2/3 antibody, respectively. Figure 3.15 shows SUMOylated 
Elk1. Elk1 has 44.8 kDa molecular weight without any modifications. SUMO group 
which is approximately 12 kDa changes the size of Elk1. 
 
Figure 3.15: Western blot analysis of Elk1 with SUMO modification. 
The 3 bands seen each columns belong to SUMOylated Elk1 with different patterns. 
Results were normalized against β-actin and histograms of total amounts of 3 bands 
were generated for both SUMO-1 (Figure 3.16) and SUMO-2/3 modifications 
(Figure 3.17). 
 
 
Figure 3.16: Normalized histogram showing Elk1 modified with SUMO 2/3. 
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Figure 3.17: Normalized histogram showing Elk1 modified with SUMO 1. 
Lu et al. (2009) revealed that when cells were exposed to depolarization buffer 
including 50 mM KCl, ratio of SUMO conjugation increased. Cells respond to KCl 
with elevating Ca
+2
 concentration and Ca
+2 
released into cells provides regulation of 
SUMO modifications (Lu et al., 2009).  
In the presence of KCl, it was observed that there was a distinct increase in 
sequential SUMOylation (upper two bands at lane 4) level whereas, single 
SUMOylation (lower band) level was decreased. Hence, it can be interpreted that, 
SUMO-1 conjugations are preferentially added to Elk-1 consecutively, rather than 
singly when cells were promoted with KCl. However, changes in SUMO-2/3 
modifications upon KCl treatment were different from SUMO-1 modifications. 
Multiple and serial SUMOylation was induced for SUMO-2/3 conjugations, 
furthermore, there was an increase in single SUMOylated Elk-1, as well. In the light 
of this information it can be concluded that, SUMO-1 may tend to prefer mono 
conjugated modifications whereas SUMO-2/3 may tend to prefer multi conjugated 
modifications in normal condition. 
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4. CONCLUSION AND RECOMMENDATION 
In this study, the effects of Elk1on SPG4 and KATNB1 gene promoter have been 
determined. Elk1 has repressive effect on SPG4 promoter whereas activator effect on 
KATNB1 promoter. The results of expression assay have been confirmed both in 
mRNA and protein levels. Then, the effect of Elk1 on SPG4 and KATNB1 promoter 
has been reversed by PMA and KCl treatment, respectively. PMA treated cells have 
shown higher spastin promoter activity; while KCl treated cells have shown lower 
p80-katanin promoter activity than wt-Elk1. 
We have shown that regulation of spastin and p80-katanin expression were Elk1 
dependent. However, expressional regulations of these proteins could also be 
investigated with different transcription factors. In addition to this, we know the 
importance of CpG islands on the promoter regions which would drive the attention 
to the CpG island methylation as an important mechanism for gene expression. 
Therefore, we suggest that CpG island methylations, as an epigenetic regulation, 
might be another regulatory mechanism resulting in different expression levels of 
spastin and p80-katanin proteins. 
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APPENDICES 
APPENDIX A. Elk1 Binding Site and SRE on KATNB1 Optimal Promoter 
Sequence 
ATCTGCAGGCAAAGTGAAGAATGAGGAGCTTCGGCAAAATGCCGACTAAGGCCTCCTTA
GGTTTTGCCCCACTCCAAGATGGAAGGCCTGAGGCTTCACACTGCCCCCGAAGTTCCTTT
CCCATTGGCTATCTGGGAATTGAGTTTTCCAATAATGCGGACGCTGATTGGTCAATCCAG
GACGGTTGCTCAAGCCATTGGCGCAGCCGCCATTGGAGGGCGGCTCTCAAAAGTTTTCAG
ACACAAATTAGGTTCGAGGGAGGAAACGGAGAGGAAAGGGAAAACTTGAGACGGAGGC
GGGACTAAGGAAACGGCAGCTTGCATTGGTTTATTAGAGGCCAAGGGGCGGCTCTTGAA
CGTTCCTTCCTCTTGATTAGTCCTATTTAGGAAAAGAGGGCGGGTACTGAGGAAAAGCGG
CAGAAGCGCCTGCTTCCATTGGTCAGTCCTGGCAGGAGGCGGAGCACCCGCGGCAGCTG
ATTGGTGCGGGAGGCAAGGTGGGCGGGGCTCTGAGCCGGAGGT 
* Elk1 binding site and SRE were highlighted yellow and pink respectively. 
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